CN111892592A - Jak激酶抑制剂及其用途 - Google Patents
Jak激酶抑制剂及其用途 Download PDFInfo
- Publication number
- CN111892592A CN111892592A CN202010776163.4A CN202010776163A CN111892592A CN 111892592 A CN111892592 A CN 111892592A CN 202010776163 A CN202010776163 A CN 202010776163A CN 111892592 A CN111892592 A CN 111892592A
- Authority
- CN
- China
- Prior art keywords
- substituted
- independently selected
- unsubstituted
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000042838 JAK family Human genes 0.000 title claims abstract description 13
- 108091082332 JAK family Proteins 0.000 title claims abstract description 13
- 229940043355 kinase inhibitor Drugs 0.000 title abstract description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 97
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 210000000845 cartilage Anatomy 0.000 claims abstract description 12
- 229940002612 prodrug Drugs 0.000 claims abstract description 11
- 239000000651 prodrug Substances 0.000 claims abstract description 11
- 239000012453 solvate Substances 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 7
- 210000000056 organ Anatomy 0.000 claims abstract description 7
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 239000002158 endotoxin Substances 0.000 claims abstract description 5
- 230000028993 immune response Effects 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 44
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 22
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- -1 formylamino Chemical group 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 12
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 12
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 12
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 150000003254 radicals Chemical class 0.000 claims description 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 9
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims description 7
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 claims description 7
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 7
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 claims description 7
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 229940124530 sulfonamide Drugs 0.000 claims description 7
- 150000003456 sulfonamides Chemical class 0.000 claims description 7
- CNRNYORZJGVOSY-UHFFFAOYSA-N 2,5-diphenyl-1,3-oxazole Chemical compound C=1N=C(C=2C=CC=CC=2)OC=1C1=CC=CC=C1 CNRNYORZJGVOSY-UHFFFAOYSA-N 0.000 claims description 6
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims description 6
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 6
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 6
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 6
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 230000008355 cartilage degradation Effects 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000004185 ester group Chemical group 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 229930192474 thiophene Natural products 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 5
- 238000006731 degradation reaction Methods 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims description 4
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 208000028004 allergic respiratory disease Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 229950007432 endomycin Drugs 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 230000036244 malformation Effects 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 230000007306 turnover Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000007850 degeneration Effects 0.000 abstract description 5
- 238000002054 transplantation Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 93
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 238000002360 preparation method Methods 0.000 description 57
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 38
- 239000007787 solid Substances 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 36
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 35
- 238000012360 testing method Methods 0.000 description 34
- 238000004587 chromatography analysis Methods 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 17
- 241000700159 Rattus Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 108010024121 Janus Kinases Proteins 0.000 description 14
- 102000015617 Janus Kinases Human genes 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- XLBCMNCPMMPNHH-UHFFFAOYSA-N n-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide Chemical compound N=1N2C(Br)=CC=CC2=NC=1NC(=O)C1CC1 XLBCMNCPMMPNHH-UHFFFAOYSA-N 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- MZJWWGUFPZKMSN-UHFFFAOYSA-N N-[5-(5-formylthiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound O=CC1=CC=C(S1)C1=CC=CC=2N1N=C(N=2)NC(=O)C1CC1 MZJWWGUFPZKMSN-UHFFFAOYSA-N 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 7
- 125000001931 aliphatic group Chemical group 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- DEQOVKFWRPOPQP-UHFFFAOYSA-N (5-formylthiophen-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)S1 DEQOVKFWRPOPQP-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- YMLQFCPQLXQXLW-UHFFFAOYSA-N N-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-N-(cyclopropanecarbonyl)cyclopropanecarboxamide Chemical compound BrC1=CC=CC2=NC(=NN12)N(C(=O)C1CC1)C(=O)C1CC1 YMLQFCPQLXQXLW-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 210000001612 chondrocyte Anatomy 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- AFCPXIWBBSGHAO-UHFFFAOYSA-N methyl 2-amino-[1,2,4]triazolo[1,5-a]pyridine-5-carboxylate Chemical compound COC(=O)C1=CC=CC2=NC(N)=NN12 AFCPXIWBBSGHAO-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- FMPFFNWSXXHSHD-RITPCOANSA-N (1S,2S)-N-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-2-fluorocyclopropane-1-carboxamide Chemical compound C1[C@H]([C@H]1F)C(=O)NC2=NN3C(=N2)C=CC=C3Br FMPFFNWSXXHSHD-RITPCOANSA-N 0.000 description 5
- CCKPICPXJWZTFV-UHFFFAOYSA-N BrCC1=NC=C(S1)B1OC(C(O1)(C)C)(C)C Chemical compound BrCC1=NC=C(S1)B1OC(C(O1)(C)C)(C)C CCKPICPXJWZTFV-UHFFFAOYSA-N 0.000 description 5
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 5
- CLLGPOGDXRZDRK-UHFFFAOYSA-N N-[5-[5-(hydroxymethyl)thiophen-2-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound OCC1=CC=C(S1)C1=CC=CC=2N1N=C(N=2)NC(=O)C1CC1 CLLGPOGDXRZDRK-UHFFFAOYSA-N 0.000 description 5
- 101100119347 Plasmodium falciparum EXP-1 gene Proteins 0.000 description 5
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000004012 Tofacitinib Substances 0.000 description 5
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- QVXACZCIJWUOQQ-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)pyrazole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=C(CCO)C=N1 QVXACZCIJWUOQQ-UHFFFAOYSA-N 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229960001350 tofacitinib Drugs 0.000 description 5
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical group C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- XXGQGFIISHCNSE-UHFFFAOYSA-N 4-(trifluoromethoxy)piperidine Chemical compound FC(F)(F)OC1CCNCC1 XXGQGFIISHCNSE-UHFFFAOYSA-N 0.000 description 4
- TVGFHUIJNZRKFW-UHFFFAOYSA-N 5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=CC=C(Br)N2N=C(N)N=C21 TVGFHUIJNZRKFW-UHFFFAOYSA-N 0.000 description 4
- LGEYLALWDKSHHR-UHFFFAOYSA-N 5-bromoimidazo[1,2-a]pyridin-2-amine Chemical compound BrC1=CC=CC2=NC(N)=CN21 LGEYLALWDKSHHR-UHFFFAOYSA-N 0.000 description 4
- YETVWHXKIRPRJC-UHFFFAOYSA-N BrC1=CC=CC=2N1C=C(N=2)NC(OC(C)(C)C)=O Chemical compound BrC1=CC=CC=2N1C=C(N=2)NC(OC(C)(C)C)=O YETVWHXKIRPRJC-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- BUOCXFZKVYZNES-RNFRBKRXSA-N O=C([C@H](C1)[C@@H]1F)NC1=CN2C(Br)=CC=CC2=N1 Chemical compound O=C([C@H](C1)[C@@H]1F)NC1=CN2C(Br)=CC=CC2=N1 BUOCXFZKVYZNES-RNFRBKRXSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000000544 articulatio talocruralis Anatomy 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 108010012052 cytochrome P-450 CYP2C subfamily Proteins 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- VJMNOJHFYDPFKP-UHFFFAOYSA-N ethyl 5-bromoimidazo[1,2-a]pyridine-2-carboxylate Chemical compound BrC1=CC=CC2=NC(C(=O)OCC)=CN21 VJMNOJHFYDPFKP-UHFFFAOYSA-N 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 210000001145 finger joint Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 210000001853 liver microsome Anatomy 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 210000003857 wrist joint Anatomy 0.000 description 4
- IIPRGRYUHTUDEC-UHFFFAOYSA-N 2-(1H-pyrazol-4-yl)ethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCC2=CNN=C2 IIPRGRYUHTUDEC-UHFFFAOYSA-N 0.000 description 3
- OTRXOKOMHXXKKN-UHFFFAOYSA-N 5-bromoimidazo[1,2-a]pyridine-2-carboxylic acid Chemical compound BrC1=CC=CC2=NC(C(=O)O)=CN21 OTRXOKOMHXXKKN-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 3
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 229950006663 filgotinib Drugs 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 description 3
- 229960004247 tofacitinib citrate Drugs 0.000 description 3
- HZQKMZGKYVDMCT-PWNYCUMCSA-N (1s,2r)-2-fluorocyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@@H]1C[C@H]1F HZQKMZGKYVDMCT-PWNYCUMCSA-N 0.000 description 2
- HZQKMZGKYVDMCT-GBXIJSLDSA-N (1s,2s)-2-fluorocyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@@H]1C[C@@H]1F HZQKMZGKYVDMCT-GBXIJSLDSA-N 0.000 description 2
- WYVAWIXRBQVQLN-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)ethanamine;hydrochloride Chemical compound Cl.NCCC1=NC=CS1 WYVAWIXRBQVQLN-UHFFFAOYSA-N 0.000 description 2
- YVQFZSHMTCZYMI-UHFFFAOYSA-N 2-(1h-pyrazol-4-yl)ethanol Chemical compound OCCC=1C=NNC=1 YVQFZSHMTCZYMI-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QXMZPGMBRRZCDV-UHFFFAOYSA-N 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-thiazole Chemical compound S1C(C)=NC=C1B1OC(C)(C)C(C)(C)O1 QXMZPGMBRRZCDV-UHFFFAOYSA-N 0.000 description 2
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- OQGIKNPOYTVNNF-UHFFFAOYSA-N 5-boronothiophene-2-carboxylic acid Chemical compound OB(O)C1=CC=C(C(O)=O)S1 OQGIKNPOYTVNNF-UHFFFAOYSA-N 0.000 description 2
- BKLJUYPLUWUEOQ-UHFFFAOYSA-N 6-bromopyridin-2-amine Chemical compound NC1=CC=CC(Br)=N1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000957383 Homo sapiens Cytochrome P450 2B6 Proteins 0.000 description 2
- 101000896586 Homo sapiens Cytochrome P450 2D6 Proteins 0.000 description 2
- 101000896576 Homo sapiens Putative cytochrome P450 2D7 Proteins 0.000 description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010033104 M-81 Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- FMPFFNWSXXHSHD-PHDIDXHHSA-N O=C([C@H](C1)[C@@H]1F)NC1=NN2C(Br)=CC=CC2=N1 Chemical compound O=C([C@H](C1)[C@@H]1F)NC1=NN2C(Br)=CC=CC2=N1 FMPFFNWSXXHSHD-PHDIDXHHSA-N 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102100021702 Putative cytochrome P450 2D7 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
- 206010046799 Uterine leiomyosarcoma Diseases 0.000 description 2
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 2
- BDTDECDAHYOJRO-UHFFFAOYSA-N ethyl n-(sulfanylidenemethylidene)carbamate Chemical compound CCOC(=O)N=C=S BDTDECDAHYOJRO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- OHIHEJTUXNQOPM-UHFFFAOYSA-N methyl 6-aminopyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(N)=N1 OHIHEJTUXNQOPM-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- AWQVKAURKXXOCG-UHFFFAOYSA-N n-cyclopropylformamide Chemical compound O=CNC1CC1 AWQVKAURKXXOCG-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229960001404 quinidine Drugs 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SSEBTPPFLLCUMN-CYBMUJFWSA-N (1r)-2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol Chemical compound CCC1=CC=CC2=C1OC([C@H](O)CNC(C)(C)C)=C2 SSEBTPPFLLCUMN-CYBMUJFWSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical group CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical compound O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- XXZCIYUJYUESMD-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(morpholin-4-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCOCC1 XXZCIYUJYUESMD-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- RZPFVRFSYMUDJO-UHFFFAOYSA-N 2h-naphthalen-1-one Chemical class C1=CC=C2C(=O)CC=CC2=C1 RZPFVRFSYMUDJO-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- FHZALEJIENDROK-UHFFFAOYSA-N 5-bromo-1h-imidazole Chemical compound BrC1=CN=CN1 FHZALEJIENDROK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- ZQFQRCIWBFVDPX-UHFFFAOYSA-N C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(S4)COCCC5=CNN=C5 Chemical compound C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(S4)COCCC5=CNN=C5 ZQFQRCIWBFVDPX-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000004427 Collagen Type IX Human genes 0.000 description 1
- 108010042106 Collagen Type IX Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101000999373 Homo sapiens Interferon-related developmental regulator 2 Proteins 0.000 description 1
- 102100036480 Interferon-related developmental regulator 2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- RWNRZBMAJDGVBV-ZIAGYGMSSA-N O=C([C@H](C1)[C@@H]1F)NC1=NN2C(C3=CC=C(CN(CC4)CCC4(F)F)S3)=CC=CC2=N1 Chemical compound O=C([C@H](C1)[C@@H]1F)NC1=NN2C(C3=CC=C(CN(CC4)CCC4(F)F)S3)=CC=CC2=N1 RWNRZBMAJDGVBV-ZIAGYGMSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229950006886 bufuralol Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000008367 cartilage synthesis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 150000001942 cyclopropanes Chemical class 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000000495 immunoinflammatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XQQLJWFNDMEBHP-UHFFFAOYSA-N n-ethyl-2-methyl-n-(2-methylpropyl)propan-1-amine Chemical compound CC(C)CN(CC)CC(C)C XQQLJWFNDMEBHP-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000013577 regulation of ventricular cardiomyocyte membrane repolarization Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000009750 upstream signaling Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
本发明公开JAK激酶抑制剂及其用途,所述JAK激酶抑制剂为式I所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药,本发明还提供本发明式I的化合物在用于制备预防或治疗JAK激酶相关疾病药物中的用途,特别是在制备用于预防和/或治疗涉及软骨退化、骨和/或关节退化的疾病、涉及炎症或免疫响应的病症、内毒素驱动的疾病状态、癌症和器官移植排斥的药物中的应用。
Description
技术领域
本发明属于医药技术领域,具体涉及一种新颖的含氮五元杂环并吡啶类化合物、其制备方法及含有其的药物组合物,以及其用于调节Janus激酶(JAK)活性并且用于治疗和/或预防与JAK活性相关的疾病的用途。
背景技术
软骨细胞是无血管组织的主要细胞组分,正常关节软骨中软骨细胞占组织体积的约5%,而细胞外基质占组织剩余的95%。软骨细胞分泌基质组分,主要是蛋白聚糖和胶原,其反过来为软骨细胞在机械压力下提供适合于它们生存的环境。在软骨中,II型胶原与IX型蛋白胶原形成纤维样结构,为软骨提供很大的机械强度。蛋白聚糖可以吸收水并且负责软骨的弹性和减震性质。软骨的功能性作用之一是为骨头部分提供彼此光滑的关节连接。因此,关节软骨的损耗引起骨彼此摩擦,导致疼痛和运动丧失。在炎性关节炎例如类风湿性关节炎中,软骨退化是由发炎组织(例如发炎的滑膜)分泌的蛋白酶(胶原酶)引起的。受损软骨中的软骨细胞常常显示出软骨合成活性的减弱和/或软骨退化活性的增强,软骨变性是发生类风湿性关节炎和骨关节炎的主要疾病标志。类风湿性关节炎(RA)是慢性关节变性疾病,其特征在于关节结构的炎症和破坏,可能导致关节功能性的失常引起实质性的失能和疼痛,甚至过早死亡。因此,RA治疗的目的不仅是延缓疾病,减轻病痛,保护关节破坏。
JAK激酶属于细胞质酪氨酸激酶的Janus激酶(JAK)家族,其参与细胞因子受体介导的细胞内信号转导。JAK激酶家族包括4个成员:JAK1、JAK2、JAK3和TYK2。JAK募集细胞因子受体,结合细胞因子,随后将细胞因子受体和共享的受体亚基进行二聚化。然后JAK通过自磷酸化和/或另一个JAK的转磷酸化而活化,导致受体磷酸化以及信号转导物和转录激活物(STAT)成员的募集和磷酸化。磷酸化的SATA二聚化并且转移至细胞核内,在细胞核内它们结合至细胞因子应答基因的增强子区。JAK在调控多种细胞因子受体家族的生物学应答功能中起着重要的作用。JAK1基因敲除的小鼠具有早期的出生后致死因子显型,神经***也受到损害,导致幼鼠出现先天缺陷。研究表明JAK1基因敲除小鼠会出现胸腺细胞和B细胞的分泌缺陷,JAK1基因敲除的组织对IL-6、IL-10的反应明显减弱。
临床已经确定JAK与自身免疫疾病的关联,约70%的重症联合免疫缺陷病例中检测到JAK以及上游信号传导组分r-c受体链和IL7受体的突变。因此,靶向JAK家族可以在免疫-炎症领域提供新的治疗药物。
临床上JAK家族成员JAK2涉及的病症,包括骨髓增殖性障碍、癌症特别是白血病例如急性髓性白血病、急性淋巴细胞白血病或实体瘤例如子宫平滑肌肉瘤、***癌等相关疾病。因此,靶向JAK家族的药物也可能为上述的疾病的治疗提供新的选择。
发明内容
本发明提供新颖的JAK激酶抑制剂及制备方法、包含有这些激酶抑制剂的药物组合物及其应用。
更具体而言,本发明涉及结构如式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药:
其中:
B独立选自取代或未取代的C3-C6环烷基、芳基、具有1至2个独立选自N、O和S的环杂原子的5至6元杂芳基环,其中所述的5至6元杂芳环任选地被独立选自卤素、氟代或未氟代的C1-C6烷基、氟代或未氟代的C1-C6烷氧基、氟代或未氟代的C1-C6烷基胺基的一个或多个取代基取代;
D独立选自C,N;
F、G、H、K独立选自C、N、S、O;
L1不存在或独立选自单键,-CH2-,-(CH2)xO(CH2)y-,-(CH2)xNH(CH2)y-,-CH2O-,-C(O)-,-CON(R4)-,-CH2N(R4)-,-CONH(CH2)y-,-N(R4)-,-SO2N(R4)-,-S(O)2-,-N(Me)-;
R4独立选自H、C1-C6烷基、取代的C1-C6烷基、C1-C3醚C1-C3烷基、甲磺酰基;
R1独立选自H、-NH2、-COOH、取代或未取代的C1-C6烷基、酰基、取代的或未取代的酰基胺基、取代的或未取代的C1-C6烷氧基、卤素、羟基、取代的或未取代的C1-C3酯基、取代或未取代的杂芳基;
R2不存在或独立选自H、F、Cl、Me;
R3独立地选自H、取代或未取代的以下基团:磺酰基、磺酰胺基、5至6元杂环,其具有至少一个杂原子且任选地具有独立选自N和S的第二环杂原子、取代的或未取代的C1-C6烷烃,取代基独立选自5至6元杂芳基和甲氧基取代、取代的或未取代的C3-C7环烷基、取代的或未取代的4-7元杂环烷基、取代的或未取代的5-7元杂芳基;
m是0、1、2、3;n是0,1、2、3;p是0、1、2;t是0、1、2、3。
在一些实施例中,F、G、H、K不同时为C。
在一种实施方式中,B选自取代或未取代的以下基团:环丙烷、环丁烷、吡唑基、吡啶基、咪唑基;取代基选自F、Cl、Br、甲基、乙基、丙基、异丙基、三氟甲基。
在一种具体的实施例中,B为取代或未取代的环丙烷;取代基选自F、Cl、Br、甲基、乙基、丙基、异丙基、三氟甲基。
在一种实施方式中,D为C或N。
在一种具体的实施例中,D为N。
在一种实施方式中,n为1。
在一种实施方式中,K为S,F、G、H为C。
在一种实施方式中,R1独立选自H、-NH2、-COOH、羟基、卤素、取代或未取代的C1-C3烷基、取代或未取代的C1-C3酰基、取代的或未取代的C1-C3酰基胺基、取代的或未取代的C1-C3烷氧基、取代的或未取代的C1-C3酯基;在一种优选的实施方式中,R1独立选自H、-NH2、-COOH、羟基、卤素、甲基、乙基、丙基、异丙基、甲酰基胺基、甲酯基。
在一种实施方式中,m为0或者1,更优选的,m为0。
在一种实施方式中,R2不存在或为H。
在一种具体的实施例中,R2不存在。
在一种实施方式中,p为0。
在一种实施方式中,L1不存在或独立选自单键,-CH2-,-(CH2)xO(CH2)y-,-(CH2)xNH(CH2)y-,-CONH(CH2)y-,-N(R4)-;R4独立选自H、甲基、乙基、丙基、乙基甲醚、甲基甲醚、乙基***;x或y独立的选自0、1或2。在一种更优选的实施方式中,L1不存在或独立选自单键,-CH2-,-(CH2)xO(CH2)y-,-(CH2)xNH(CH2)y-,-CONH(CH2)y-,-N(R4)-;在一些更为具体的实施例中,L1选自-CH2-,-(CH2)xO(CH2)y-,-CONH(CH2)y-,R4独立选自H、甲基、乙基甲醚;x或y独立的选自0、1或2;在一些具体的实施例中,x或y独立的选自1或2。
在一种实施方式中,t为1。
在一种实施方式中,R3独立地选自H、取代或未取代的以下基团:磺酰基、磺酰胺基、硫代吗啉1,1-二氧化物、哌啶、吡唑、噻唑、咪唑、1,3,4-噻二唑、哌嗪、吗啉、噻吩、噁唑、1,3,4-噁二唑、呋喃、吡咯、3-吡咯啉、2-吡唑啉、1,2,3-唑、1,2,3-***、1,2,4-***、吡喃;取代基选自H、卤素、C1-C3烷基、C1-C3卤代烷基、羟基C1-C3烷基、C3-C6环烷基、乙基甲醚、甲基甲醚、乙基***;在一些实施例中,取代基还可以选自C1-C3卤代烷氧基;优选的,R3独立地选自H、取代或未取代的以下基团:磺酰基、磺酰胺基、硫代吗啉1,1-二氧化物、哌啶、吡唑、噻唑、咪唑、1,3,4-噻二唑、哌嗪、吗啉、吡嗪、噻吩、噁唑、1,3,4-噁二唑、呋喃、吡咯、3-吡咯啉、2-吡唑啉、1,2,3-唑、1,2,3-***、1,2,4-***、吡喃;取代基选自H、卤素、甲基、乙基、丙基、异丙基、三氟甲基、羟乙基、羟甲基、环丙烷、环丁烷、乙基甲醚、甲基甲醚、乙基***;在一些实施例中,取代基还可以选自三氟甲氧基。
本发明还提供以下结构所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药:
本发明还提供了合成本发明化合物的方法以及公开的代表性的合成方案和路线。
本发明还提供一种药物组合物,其包含本发明所述的式I的化合物或其药学上可接受的盐,和药学上可接受的稀释剂或载体。
本发明还提供本发明式I的化合物在用于制备预防或治疗JAK激酶相关疾病药物中的用途,特别是在制备用于预防和/或治疗涉及软骨退化、骨和/或关节退化的疾病、涉及炎症或免疫响应的病症、内毒素驱动的疾病状态、癌症和器官移植排斥的药物中的应用。
本发明还提供一种通过施用本发明所述化合物预防和/或治疗涉及软骨退化、骨和/或关节退化的疾病、涉及炎症或免疫响应的病症、内毒素驱动的疾病状态、癌症和器官移植排斥的方法。
在一种实施例中,本发明所述的涉及软骨退化、骨和/或关节退化的疾病、涉及炎症或免疫响应的病症、内毒素驱动的疾病状态、癌症和器官移植排斥的实例包括但不限于:骨关节炎、克隆病、类风湿性关节炎、银屑病、过敏性气道疾病(例如哮喘、鼻炎)、幼年特发性关节炎、结肠炎、炎性肠病、内霉素驱动的疾病状态、软骨更新损伤的疾病(例如软骨细胞的合成代谢兴奋的疾病)、先天软骨畸形、器官移植排斥、涉及软骨退化、关节退化、骨髓增殖性障碍、白血病(急性髓性白血病、急性淋巴细胞白血病)、实体瘤(子宫平滑肌肉瘤、***癌)等。
定义
本申请使用的术语“氨基”是指具有1个氮原子及1至2个氢原子的官能团。“氨基”在本文通常用于描述伯胺、仲胺或叔胺且本领域技术人员能够根据本公开中使用该术语的上下文而容易地确定所述氨基。术语“胺”或“胺基团”或“氨基团”是指含有衍生自氨(NH3)的氮原子的官能团。胺基团优选为伯胺,其意指氮结合至两个氢原子和一个包含取代或未取代的烷基或芳基或脂族或芳族基团的取代基。胺基团可以是仲胺,其意指氮结合至一个氢原子和两个包含如下文所定义的取代或未取代的烷基或芳基或脂族或芳族基团的取代基。胺基团可以是叔胺,其意指但结合至三个包含取代或未取代的烷基或芳基或脂族或芳族基团的取代基。胺基团也可以是季胺,其意指所指定的胺基团结合至第四个基团,这产生带正电荷的铵基团;
应理解的是,本发明中的任何或所有胺可以为游离胺形式(即对于伯胺而言为-NH2)或与药学上可接受的阴离子形成的质子化形式(即对于伯胺而言为-NH3 +Y-,其中Y-为药学上可接受的阴离子);
如本文所用,术语“酰胺基团”是指包含连接至氮的羰基的官能团。“羰基”是指包含以双键键合至氧原子的碳原子的官能团,其以(C=O)表示;
术语“烷烃”是指通过单键键合的饱和烃。烷烃可以是直链或支链的。“环烷烃”是通过单键键合的饱和烃环;
如本文所用,术语“C1-C6烷基”是指饱和直链或支链或环状烃,其基本上由1至6个碳原子和相应数量的氢原子构成。典型地,直链或支链基团具有1至10个碳,或更典型地1至5个碳。示例性的C1-C6烷基包括甲基、乙基、正丙基、异丙基、正丁基、异丁基等。根据本公开的教导,其他C1-C6烷基对于本领域技术人员将显而易见的;
如本文所用,术语“C2-C9杂烷基”是指饱和直链或支链或环状烃,其基本上由2至10个原子构成,其中2至9个原子为碳且其余原子选自氮、硫和氧。根据本公开的教导,示例性的C2-C9杂烷基对于本领域的技术人员而言将是显而易见的;
如本文所用,术语“C3-C10环烷基”是指非芳族饱和烃基团,其形成至少一个基本上由3至10个碳原子和相应数量的氢原子构成的环。C3-C10环烷基可以是单环的或多环的。除了共价键以外,多环环烷基的各个环可具有不同的连接性,例如稠合、桥连、螺环等;
如本文所用,术语“C2-C9杂环烷基”是指具有3至10个原子以形成至少一个环的非芳族基团,其中2至9个环原子为碳且其余原子选自氮、硫和氧。C2-C9杂环烷基可以是单环的或多环的。除了共价键取代以外,此类多环杂环烷基的各个环可能具有不同的连接性,例如稠合、桥连、螺环等。根据本公开的教导,示例性的C2-C9杂环烷基对于本领域的技术人员而言将是显而易见的;
术语“脂族基团”或“脂族基”是指由碳和氢构成的非芳族基团且可任选包括一个或多个双键和/或叁键。换言之,脂族基团是由碳和氢构成且不含芳族官能性的任何基团。脂族基团可以是直链的、支链的或环状的且典型地含有1至24个碳原子;
术语“芳基基团”可与“芳基”、“芳基环”、“芳族基”、“芳族基团”和“芳族环”互换使用。芳基包括碳环芳族基团,其典型地具有6至14个环碳原子。芳基也包括杂芳基,其典型地具有5至14个环原子,其中一个或多个杂原子选自氮、氧和硫;
如本文所用,术语“C6-C14芳基”是指具有6至14个碳原子以形成至少一个环的芳族官能团;
如本文所用,术语“C2-C9杂芳基”是指具有5至10个原子以形成至少一个环的芳族官能团,其中2至9个环原子为碳且其余环原子选自氮、硫和氧。C2-C9杂芳基可以是单环的或多环的。除了共价键取代以外,此类多环杂芳基的各个环可具有不同的连接性,例如稠合、桥连、螺环等。C2-C9杂芳基典型地经碳原子而连接至主结构,然而本领域技术人员将了解某些其他原子例如杂环原子何时连接至主结构。根据本公开的教导,其他C2-C9杂芳基对于本领域技术人员而言将是显而易见的;
如本文所用,术语“烷基胺”是指含伯、仲或叔胺基团以代替一个氢原子的C1-C6烷基,其以C1-C6烷基胺和(C1-C6烷基)2胺表示;
术语“烷基酯”是指含有酯基团以代替一个氢原子的C1-C6烷基,其以-O(O)C(C1-C6烷基)表示;
术语“烷基酸”是指含有羧酸基团以代替一个氢原子的C1-C6烷基,其以C1-C6烷基-COOH表示;
术语“脂肪酸”是指非芳族烃的酸,其以C1-C6烷基-COOH和C3-C6烷基-COOH表示;
术语“卤素”是指氟(F)、氯(Cl)、溴(Br)、碘(I)或砹(At)离子;
术语“甲氧基”是指含有氧以代替一个氢原子的(C1)烷基,其以-(O)CH3表示;
术语“多元醇”是指含有多个羟基的醇;
“取代”是指烷基、杂环基或芳基的碳经一个或多个非碳取代基取代。非碳取代基选自氮、氧和硫;
“未取代”是指基团仅包含氢和碳。
“酯基”表示-C(O)O-R’基团,其中R’定义同上,但是R’不能是氢。
“烷基磺酰基”代表式-SO2R所示的基团,R表示烷基。
“磺酰基”表示-S(O2)-;
“磺酰胺基”表示-S(O2)NH-;
具体实施方式
以下结合实施例进一步描述本发明,但这些实施例并非限制着本发明的范围,凡在本发明的构思前提下对本发明制备方法的简单改进都属于本发明的保护范围之内。下面实施例未注明具体条件的实验方法,通常按照本领域的公知手段。下述实施例中所用的试验材料,如无特殊说明,均为自常规生化试剂商店购买得到的。
实施例1:化合物EXP-1的制备
合成路线如下:
步骤1.1化合物1的制备
5-溴-[1,2,4]***并[1,5-a]吡啶-2-胺(SM1)(2g,9.4mmol)和三乙胺(2.4g,23.5mmol)溶于乙腈(10mL)中,在0℃下滴加环丙基甲酰氯(SM2)(2.45g,23.5mmol),自然升到室温搅拌16小时。反应液真空浓缩得到双酰基化中间体N-(5-溴-[1,2,4]***并[1,5-a]吡啶-2-基)-N-(环丙烷羰基)环丙烷甲酰胺(1)(3.3g粗品,黄色固体),无需进步纯化可直接用于下一步。
LCMS:tR=0.785min in 5-95AB_1.5min_220&254_Shimadzu.lcmchromatography(Agilent Pursult 5C18 20*2.0mm),MS(ESI)m/z=350.9[M+2+H]+.
步骤1.2化合物Int-1的制备
N-(5-溴-[1,2,4]***并[1,5-a]吡啶-2-基)-N-(环丙烷羰基)环丙烷甲酰胺(1)(3.3g粗品,9.4mmol)溶于甲醇(30mL)溶液中,加入碳酸钾(3.9g,28.2mmol),室温搅拌1小时。反应液室温下真空浓缩,得到的粗品用乙酸乙酯(250mL)溶解分散后过滤,滤饼用二氯甲烷(250mL)和四氢呋喃(250mL)依次洗涤,收集滤液真空浓缩,用石油醚/乙酸乙酯(22mL,10:1v/v)进步打浆后得到产物N-(5-溴-[1,2,4]***并[1,5-a]吡啶-2-基)环丙烷甲酰胺(Int-1)(2.14g,收率80%,纯度99%),黄色固体。
LCMS:tR=0.699min in 5-95AB_1.5min_220&254_Shimadzu.lcmchromatography(Merk RP18e 25-3mm),MS(ESI)m/z=282.9[M+H+2]+.
1H NMR(400MHz,DMSO-d6):δ=11.21(br s,1H),7.71(dd,J=8.4,0.8Hz,1H),7.56(t,J=7.2Hz,1H),7.50(dd,J=7.6,0.6Hz,1H),2.04(br s,1H),0.85-0.82(m,4H).
步骤1.3化合物2的制备
N-(5-溴-[1,2,4]***并[1,5-a]吡啶-2-基)环丙烷甲酰胺(Int-1)(300mg,1.1mmol),(5-甲酰基-2-噻吩基)硼酸(SM3)(332.9mg,2.1mmol)和碳酸钾(442.5mg,3.2mmol)溶于二氧六环(5mL)和水(1mL)中,置换氮气三次后快速加入1,1-双(二苯基磷)二茂铁氯化钯(39.0mg,53.4umol),再次置换氮气三次,在氮气保护下90℃搅拌30分钟。反应液用水(20mL)和二氯甲烷稀释萃取(20mL×3),有机相用饱和食盐水(20mL)洗涤,无水硫酸钠干燥后过滤,滤液真空浓缩得到粗品,硅胶柱层析纯化(洗脱剂:1%~2%甲醇/二氯甲烷)得到产品N-[5-(5-甲酰基-2-噻吩基)-[1,2,4]***并[1,5-a]吡啶-2-基]环丙烷甲酰胺(2)(350mg半纯品,含有部分原料1,折算收率49.4%),黄色固体。
LCMS:tR=0.783min in 5-95AB_1.5min_220&254_Shimadzu.lcmchromatography(Agilent Pursult 5C18 20*2.0mm),MS(ESI)m/z=312.8[M+H]+.
步骤1.4化合物EXP-1的制备
N-[5-(5-甲酰基-2-噻吩基)-[1,2,4]***并[1,5-a]吡啶-2-基]环丙烷甲酰胺(2)(220mg半纯品,331.0umol)和1,1-二氧硫代吗啉(SM4)(53.7mg,397.3umol)溶于甲醇(6mL)中,滴加醋酸调节pH值到6左右,50℃搅拌1小时,冷却到室温后加入氰基硼氢化钠(41.6mg,662.1umol),30℃继续搅拌15小时。反应液用饱和碳酸氢钠水溶液(3mL)处理,加水(10mL)稀释并用二氯甲烷萃取(20mL×3),有机相合并后用饱和食盐水(20mL)洗涤,无水硫酸钠干燥后过滤,滤液真空浓缩得到粗品,碱性制备分离纯化得到目标化合物EXP-1(28.9mg,收率20%),白色固体。
LCMS:tR=1.893min in 10-80AB_7min_220&254_Shimadzu.lcm chromatography(Xtimate C18 2.1*30mm),MS(ESI)m/z=432.0[M+H]+.
HPLC:tR=2.50min in 10-80AB_8min_Shimadzu.lcm chromatography(Ultimate3.0*50mm 3um).
1H NMR(400MHz,CDCl3):δ=8.77(s,1H),8.12(d,J=3.6Hz,1H),7.61-7.51(m,2H),7.37(dd,J=6.4,2.8Hz,1H),7.07(d,J=3.6Hz,1H),3.96(s,2H),3.18-3.06(m,8H),1.66-1.58(m,1H),1.30-1.20(m,2H),1.03-0.93(m,2H).
依据与上述实施例相同的方法,使用市售化合物或参考所示的中间化合物的制备方法而制备以下表1的实施例化合物。
【表1】
实施例2:化合物EXP-3的制备
合成路线如下:
步骤2.1化合物22的制备
将6-溴吡啶-2-胺(SM16)(5g,28.90mmol)和溴代丙酮酸乙酯(SM17)(6.20g,31.79mmol)溶于乙醇(30mL),于85度下搅拌16小时。反应液过滤,滤饼收集,用石油醚/乙酸乙酯(5/1,v/v,50mL)打浆,固体过滤,干燥得到5-溴咪唑[1,2-a]吡啶-2-羧酸乙酯(22)(8.41g,83%yield,溴化氢盐,黄色固体)。
1H NMR(400MHz,DMSO-d6):δ=8.56(s,1H),7.75(d,J=8.8Hz,1H),7.52-7.44(m,2H),4.36(q,J=7.2Hz,2H),1.34(t,J=7.2Hz,3H).
步骤2.2化合物23的制备
将5-溴咪唑[1,2-a]吡啶-2-羧酸乙酯(22)(2g,5.71mmol,溴化氢盐)溶于水,四氢呋喃和甲醇各5毫升溶剂中,加入一水合氢氧化锂(839mg,20.00mmol)。反应液于15度搅拌2小时。反应液加水(10mL),用二氯甲烷(20mL)。水相用稀盐酸(1N)调至pH=5,过滤,滤饼干燥得到5-溴咪唑[1,2-a]吡啶-2-甲酸(23)(1.24g,90%收率,白色固体)用于下一步。
LCMS:tR=0.292min in 5-95AB_1.5min_220&254_Shimadzu.lcm,chromatography(Chromolith Flash RP-18,5um,3.0*25mm),MS(ESI)m/z=241.1[M+H]+.
1H NMR(400MHz,DMSO-d6):δ=8.37(s,1H),7.72(d,J=8.8Hz,1H),7.43(dd,J=8.8,1.2Hz,1H),7.39-7.28(m,1H).
步骤2.3化合物24的制备
将5-溴咪唑[1,2-a]吡啶-2-甲酸(23)(1.24g,5.14mmol),4A分子筛(2.48g,10.29mmol)和三乙胺(1.56g,15.43mmol)悬浮于叔丁醇(12mL)中,加入叠氮磷酸二苯酯(2.12g,7.72mmol)。反应液于氮气氛围下在90度搅拌16小时。反应液过滤,滤液真空浓缩,粗品通过硅胶色谱纯化(甲醇/二氯甲烷,从0%到2%)得到5-溴咪唑[1,2-a]吡啶-2-胺基甲酸叔丁酯(24)(1.01g,49%收率,78%纯度,黄色固体)。
LCMS:tR=1.443min in 10-80AB_2min_220&254_Shimadzu.lcm,chromatography(Xtimate C18 2.1*3mm,3um),MS(ESI)m/z=312.1[M+H]+.
步骤2.4化合物25的制备
将5-溴咪唑[1,2-a]吡啶-2-胺基甲酸叔丁酯(24)(1.01g,3.24mmol)溶于二氯甲烷(20mL)中加入三氟乙酸(12.32g,108.05mmol),反应液于15度搅拌2小时。反应液浓缩,用饱和碳酸氢钠调节pH=9,然后用二氯甲烷(30mL×3)萃取。有机相合并,用食盐水(20mL)洗涤,无水硫酸钠干燥,过滤,浓缩得到粗品,通过硅胶色谱柱纯化(甲醇/二氯甲烷,从0%到5%)得到5-溴咪唑[1,2-a]吡啶-2-胺(25)(400mg,58%收率,黄色固体)。
1H NMR(400MHz,DMSO-d6):δ=7.24(d,J=8.0Hz,1H),7.06(d,J=7.2Hz,1H),7.02-6.97(m,2H),5.30(brs,2H).
步骤2.5化合物26的制备
将反式-2-氟环丙基甲酸(SM18)(491mg,4.72mmol)溶于二氯甲烷(1mL)中,零度下加入草酰氯(539mg,4.24mmol)和一滴二甲基甲酰胺,反应液于零度下搅拌1小时,然后零度下加入5-溴咪唑[1,2-a]吡啶-2-胺(25)(500mg,2.36mmol)的二甲基乙酰胺(4mL)溶液,室温下搅拌2小时。反应液(和批次EB4-106合并,投料100mg的底物1)加入饱和碳酸氢钠溶液(40mL)淬灭,用乙酸乙酯(60mL×3)萃取。有机相合并,食盐水(40mL)洗涤,无水硫酸钠干燥,过滤,真空浓缩,通过硅胶色谱柱(甲醇/二氯甲烷,从0%到2%)纯化得到反式-N-(5-溴咪唑[1,2-a]吡啶-2-基)-2-氟-环丙基甲酰胺(26)(587mg,69%收率,黄色固体)。
1H NMR(400MHz,DMSO-d6):δ=11.31(s,1H),8.02(s,1H),7.53(d,J=8.8Hz,1H),7.32-7.17(m,2H),5.07-4.75(m,1H),2.47-2.41(m,1H),1.61-1.47(m,1H),1.30-1.20(m,1H).
步骤2.6化合物27的制备
将(5-甲酰基-2-噻吩)硼酸(SM3)(419mg,2.68mmol),反式-N-(5-溴咪唑[1,2-a]吡啶-2-基)-2-氟-环丙基甲酰胺(26)(200mg,0.671mmol)和碳酸钾(278mg,2.01mmol)溶于二氧六环(4mL)和水(0.5mL)中,氮气置换3次,然后加入1,1-双(二苯基磷)二茂铁氯化钯(49mg,0.0671mmol),再次氮气置换3次,反应液100度下搅拌1小时。反应液浓缩,通过硅胶色谱柱(甲醇/二氯甲烷,从0%到2%)纯化得到反式-2-氟-N-[5-(5-甲酰基-2-噻吩)咪唑[1,2-a]吡啶-2-基]环丙基甲酰胺(27)(90mg,41%收率,100%纯度,黄色固体)。
LCMS:tR=0.832min in 5-95AB_1.5min_220&254_Shimadzu.lcm,chromatography(Xtimate C18 2.1*30mm,3um),MS(ESI)m/z=330.1[M+H]+.
步骤2.7化合物EXP-3的制备
将反式-2-氟-N-[5-(5-甲酰基-2-噻吩)咪唑[1,2-a]吡啶-2-基]环丙基甲酰胺(27)(90mg,0.273mmol)和硫代吗啉-1,1-二氧化物(SM4)(55mg,0.410mmol)溶于甲醇(4mL),二氯甲烷(2mL)和四氢呋喃(2mL)中,加入醋酸(21mg,0.355mmol),室温下搅拌2小时,加入氰基硼氢化钠(69mg,1.09mmol),反应液室温下搅拌16小时。反应液加入饱和碳酸氢钠(30mL)淬灭,室温下搅拌半小时,加入二氯甲烷(50mL×3)萃取。有机相合并,食盐水(30mL)洗涤,无水硫酸钠干燥,过滤,真空浓缩,粗品通过制备HPLC(Column:WatersXbridge 150*25mm*5um;Condition:water(0.04%NH3.H2O+10mM NH4HCO3)-ACN;Begin B,25%;End B,55%;Gradient Time:(8min);Flow Rate:(25mL/min))纯化得到反式-N-[5-[5-[(1,1-二氧代-1,4-噻嗪-4-基)甲基]-2-噻吩]咪唑[1,2-a]吡啶-2-基]-2-氟-环丙基甲酰胺(EXP-3)(22.4mg,17%收率,96.17%纯度,黄色固体)。
LCMS:tR=1.765min in 10-80AB_4min_220&254_Shimadzu.lcm,chromatography(Xtimate C18 2.1*3mm,3um),MS(ESI)m/z=449.2[M+H]+.
HPLC:tR=2.36min in10-80AB_8min_215&220&254.met.
1H NMR(400MHz,DMSO-d6):δ=11.25(s,1H),8.30(s,1H),7.56(d,J=3.6Hz,1H),7.49(d,J=9.2Hz,1H),7.32(dd,J=9.2,7.2Hz,1H),7.20(d,J=3.6Hz,1H),7.07(d,J=7.2Hz,1H),5.03-4.70(m,1H),4.01(s,2H),3.17-3.10(m,4H),3.03-2.93(m,4H),2.48-2.40(m,1H),1.62-1.45(m,1H),1.28-1.16(m,1H).
实施例3:化合物EXP-4的制备
合成路线如下:
步骤3.1化合物3的制备
将2-甲基噻唑-5-硼酸嚬哪醇酯(SM5)(100mg,0.444mmol)溶于四氯化碳中(2mL),加入N-溴代丁二酰亚胺(103mg,0.577mmol)和偶氮二异丁腈(7.3mg,0.0444mmol)。反应液在氮气保护下于80℃搅拌0.5小时。反应液过滤,滤液真空浓缩得粗品,然后溶于四氢呋喃(2mL)中,依次加入二异丙基乙胺(0.1mL)和亚磷酸二乙酯(74uL),在10℃搅拌25分钟得到2-溴甲基噻唑-5-硼酸嚬哪醇酯(3)(135mg,粗品,溶于2mL四氢呋喃的棕色溶液),直接用于下一步。
LCMS:tR=0.590min in 5-95AB_1.5min_220&254_Shimadzu.lcmchromatography(Merk RP18e 25-3mm),MS(ESI)m/z=221.7[M-81]+.
步骤3.2化合物4的制备
将2-溴甲基噻唑-5-硼酸嚬哪醇酯(3)(135mg,0.444mmol)和碳酸钾(246mg,1.78mmol)悬浮在四氢呋喃(2mL)中,加入硫代吗啉-1,1-二氧化物(SM4)(72mg,0.533mmol)。反应液氮气保护下在10℃反应24小时。反应液真空浓缩得到4-[[5-(4,4,5,5-四甲基-1,3,2-二氧硼烷-2-)噻唑-2-]甲基]-1,4-噻嗪1,1-二氧化物(4)(159mg,粗品,红色固体),直接用于下一步。
LCMS:tR=0.287min in 5-95AB_1.5min_220&254_Shimadzu.lcmchromatography(Merk RP18e 25-3mm),MS(ESI)m/z=276.8[M-81]+.
步骤3.3化合物EXP-4的制备
将N-(5-溴-[1,2,4]***[1,5-a]吡啶-2-基)环丙烷甲酰胺(Int-1)(20mg,0.071mmol),4-[[5-(4,4,5,5-四甲基-1,3,2-二氧硼烷-2-)噻唑-2-]甲基]-1,4-噻嗪1,1-二氧化物(4)(76.5mg,0.213mmol),碳酸钾(29.5mg,0.213mmol)悬浮在二氧六环(1mL)和水(0.2mL)中,反应液氮气置换三次,然后快速加入1,1-二(叔丁基磷)二茂铁氯化钯(9.3mg,0.014mmol),反应液再次氮气置换三次,在85℃下搅拌半个小时。反应液真空浓缩,快速过柱子机纯化(洗脱剂:0%~0.5%甲醇/二氯甲烷)得到粗品,碱性机分得到目标分子N-[5-[2-[(1,1-二氧-1,4-噻嗪-4-)甲基]噻唑-5-]-[1,2,4]***[1,5-a]吡啶-2-]环丙基甲酰胺(EXP-4)(5.6mg,6%收率,93%纯度,黄色固体)。
LCMS:tR=1.793min in 10-80AB_7min_220&254_Shimadzu.lcm,chromatography(Xtimate C18,2.1*30mm),MS(ESI)m/z=433.0[M+H]+.
HPLC:tR=2.54min in 10-80AB_8min.met(Ultimate C18 3*50mm 3um).
1H NMR(400MHz,DMSO-d6):δ=11.22(br s,1H),8.93(s,1H),7.81-7.63(m,3H),4.16(s,2H),3.23-3.04(m,8H),2.13-2.06(m,1H),0.95-0.81(m,4H).
实施例4:化合物EXP-5的制备
合成路线如下:
步骤4.1化合物5的制备
氮气保护下,顺式2-氟环丙羧酸(SM6)(50mg,0.48mmol)溶于SOCl2(1mL)中,在75℃下搅拌1小时。低于30℃减压浓缩,得到化合物顺式-2-氟环丙烷酰氯(5)(58mg,98%yield),黄色油状物直接用于下一步。
步骤4.2化合物Int-2的制备
氮气保护下,5-溴-[1,2,4]***[1,5-a]吡啶-2-胺(SM1)(100mg,0.469mmol)和顺式-2-氟环丙烷酰氯(5)(58mg,0.469mmol)溶于吡啶(1mL),加热至60℃,搅拌1小时。浓缩得粗品,溶于二氯甲烷(3mL)和(1mL)甲醇中。过滤除去不溶性固体,二氯甲烷(1mL×2)洗涤,滤液浓缩得粗品N-[5-溴-[1,2,4]***[1,5-a]吡啶-2-基]-顺式-2-氟环丙烷甲酰胺(Int-2)(130mg,粗品)黄色固体,直接用于下一步。
LCMS:tR=0.609min in 5-95AB_1.5min_220&254_Shimadzu.lcm,chromatography(Agilent Pursult 5C18 20*2.0mm),MS(ESI)m/z=300.6[M+H]+.
1H NMR(400MHz,CDCl3):δ=8.01(s,1H),7.65(d,J=8.8Hz,1H),7.40(d,J=8.4Hz,1H),7.25-7.24(m,1H),4.95-4.76(m,1H),2.08-1.94(m,1H),1.89-1.77(m,1H),1.26-1.21(m,1H).
步骤4.3化合物6的制备
N-[5-溴-[1,2,4]***[1,5-a]吡啶-2-基]-顺式-2-氟环丙烷甲酰胺(Int-2)(100mg,0.334mmol)和(5-甲酰-2-噻吩)硼酸(SM3)(261mg,1.67mmol),和碳酸钠(106mg,1.00mmol)溶于四氢呋喃(2mL)和水(1mL)中,氮气置换三次后加入1,1-双(二苯基磷)二茂铁氯化钯(47mg,0.067mmol),氮气置换三次后升到100℃搅拌0.5小时。反应液加水(20mL)搅拌,乙酸乙酯(40mL)萃取,有机相用饱和食盐水(10mL)洗涤,无水硫酸钠干燥后过滤,滤液真空浓缩得到粗品黄色固体N-[5-(2-甲酰基)-噻吩-[1,2,4]***[1,5-a]吡啶-2-基]-顺式-2-氟-环丙烷甲酰胺(6)(100mg,粗品)直接用于下一步。
步骤4.4化合物EXP-5的制备
N-[5-(2-甲酰基)-噻吩-[1,2,4]***[1,5-a]吡啶-2-基]-顺式-2-氟-环丙烷甲酰胺(6)(100mg,0.302mmol)和1,1-二氧硫代吗啉(SM4)(82mg,0.605mmol)溶于甲醇(5mL)中,加入醋酸(9mg,0.151mmol),然后加热到80℃反应0.2小时,降至室温加入氰基硼氢化钠(152mg,2.42mmol),再加热至80℃反应0.5小时,降温,加入饱和碳酸氢钠(10mL),室温搅拌0.5小时,浓缩掉大部分甲醇然后乙酸乙酯(20mL×2)萃取,浓缩,溶于甲醇(5mL)中,制备分离纯化得到标题产品N-[5-[4-[(1,1-二氧硫代吗啉)甲基]噻吩基]-[1,2,4]***[1,5-a]吡啶-2-基]-顺式-2-氟-环丙烷甲酰胺(EXP-5)(10.3mg,8%yield),白色固体。
LCMS:tR=1.545min in 10-80AB_4min_220&254_Shimadzu.lcm,chromatography(Xtimate C18 2.1*30mm),MS(ESI)m/z=450.0[M+H]+.
HPLC:tR=2.43min in 10-80AB_8min_met,chromatography(Ultimate 3.0*50mm*3um).
1H NMR(400MHz,DMSO-d6):δ=11.23(brs,1H),8.26(brs,1H),7.77-7.56(m,3H),7.20(brs,1H),5.07-4.91(m,1H),4.00(brs,2H),3.14-2.98(m,8H),2.34-2.31(m,1H),1.73-1.68(m,1H),1.22-1.20(m,1H).
依据与上述实施例相同的方法,使用市售化合物或参考所示的中间化合物的制备方法而制备以下表2的实施例化合物。
【表2】
实施例5:化合物EXP-12的制备
合成路线如下:
步骤5.1化合物7的制备
将反式-N-(5-溴-[1,2,4]***[1,5-a]吡啶-2-基)-2-氟-环丙烷甲酰胺(Int-3)(100mg,0.33mmol),(5-甲酰-2-噻吩基)硼酸(SM3)(111mg,0.71mmol),碳酸钾(98mg,0.71mmol),双(三苯基磷)二氯化钯(50mg,0.07mmol)溶于水(0.5mL)和四氢呋喃(1mL)中,氮气置换3次,100℃搅拌1小时。过滤,滤饼干燥,得到粗产物,柱分离(二氯甲烷:甲醇=100∶1~20∶1)纯化,得到反式-N-(5-(5-甲酰基-2-噻吩基)-[1,2,4]***并[1,5-a]吡啶-2-基]-2-氟-环丙烷酰胺(7)(50毫克,粗品,黄色固体)。
LCMS:tR=2.054min in 10-80AB_4.0min_220&254_Shimadzu.lcm,chromatography(Xtimate C18,3um,2.1*30mm),MS(ESI)m/z=301.0[M+H]+.
步骤5.2化合物EXP-12的制备
反式-N-(5-(5-甲酰基-2-噻吩基)-[1,2,4]***并[1,5-a]吡啶-2-基]-2-氟-环丙烷酰胺(7)(25mg,0.08mmol)和4,4-二氟哌啶(SM7)(18mg,0.15mmol)溶于甲醇(3ml)中,然后加入醋酸(2mg,0.04mmol),50℃搅拌0.5小时,然后加入氰基硼氢化钠(38mg,0.61mmol),50℃再搅拌0.5小时。加入饱和碳酸氢钠(10mL),过滤,滤液浓缩,得到粗品,制备薄层色谱分离(二氯甲烷:甲醇=10:1)纯化,得到反式-N-[5-[5-[(4,4-二氟-1-哌啶基)甲基]-2-噻吩基]-[1,2,4]***[1,5-a]吡啶-2-基]-2-氟环丙烷甲酰胺(EXP-12)(5.0mg,13%收率,白色固体)。
LCMS:tR=0.985min in 5-95AB_1.5min_220&254_Shimadzu.lcm,chromatography(Xtimate C18 2.1*30mm),MS(ESI)m/z=436.1[M+H]+.
HPLC:tR=2.15min in 10-80AB_8min_met,chromatography(XBridge ShieldRP18 5um).
1H NMR(400MHz,CD3OD)δ=8.27(d,J=4.0Hz,1H),7.80-7.74(m,2H),7.67-7.64(m,1H),7.47(d,J=3.6Hz,1H),5.01-4.88(m,1H),4.69(s,2H),3.49(brs,4H),2.62-2.42(m,1H),2.38(brs,4H),1.67-1.56(m,1H),1.48-1.44(m,1H).
依据与上述实施例相同的方法,使用市售化合物或参考所示的中间化合物的制备方法而制备以下表3的实施例化合物。
【表3】
实施例6:化合物EXP-14的制备
合成路线如下:
步骤6.1化合物8的制备
将6-氨基吡啶-2-甲酸甲酯(SM8)(3g,19.72mmol)溶在二氧六环(30mL)中加入乙氧羰基异硫氰酸酯(SM9)(2.84g,21.69mmol)。10度下搅拌16小时。反应液浓缩,用乙酸乙酯/石油醚(1/15,30mL)打浆得到6-(3-(乙氧)硫脲)吡啶甲酸甲酯(8)(5.25g,94%收率,100%纯度,淡黄色固体)。
LCMS:tR=0.840min in 5-95AB_220&254_Agilent,chromatography(MERCK RP18e 25*3.0mm),MS(ESI)m/z=284.1[M+H]+.
步骤6.2化合物9的制备
将6-(3-(乙氧)硫脲)吡啶甲酸甲酯(8)(5.25g,18.53mmol)溶于甲醇(75mL)加入盐酸羟按(1.42g,20.38mmol)和二异丁基乙胺(3.11g,24.09mmol),反应液60度搅拌16小时。反应液冷却,过滤,固体收集干燥得到2.5g白色固体产物,滤液浓缩得到粗品然后过柱子纯化(甲醇/二氯甲烷,0%到2%)得到1.5g的白色固体。两批产物合并得到2-氨基-[1,2,4]***[1,5-a]吡啶-5-甲酸甲酯(9)(4g,crude,白色固体)。
1H NMR(400MHz,DMSO-d6):δ=7.62-7.58(m,1H),7.53-7.47(m,1H),7.41(dd,J=7.6,1.2Hz,1H),6.26(s,2H),3.92(s,3H).
步骤6.3化合物10的制备
将2-氨基-[1,2,4]***[1,5-a]吡啶-5-甲酸甲酯(9)(3.56g,18.52mmol)溶在二甲基乙酰胺(20mL)然后0度下加入环丙基酰氯(SM2)(3.87g,37.05mmol)。20度下搅拌3.5小时。反应液用饱和碳酸氢钠调节至pH=8。过滤,固体水洗(10mL×3)干燥得到2-(环丙甲酰氨基)-[1,2,4]***[1,5-a]吡啶-5-甲酸甲酯(10)(2.11g,44%收率,100%纯度,白色固体)。
LCMS:tR=0.573min in 5-95AB_1.5min_220&254_Agilent,chromatography(Merck RP-18e 25-3mm),MS(ESI)m/z=261.1[M+H]+.
步骤6.4化合物11的制备
将2-(环丙甲酰氨基)-[1,2,4]***[1,5-a]吡啶-5-甲酸甲酯(10)(2.11g,8.11mmol)溶于乙醇(40mL)加入水合肼(2.48g,48.65mmol,98%purity)。13度下搅拌2小时。反应液过滤,固体用乙醇(10mL)洗涤,干燥得到N-[5-(肼基酰基)-[1,2,4]***[1,5-a]吡啶-2-]环丙甲酰胺(11)(2g,95%收率,100%纯度,白色固体)。
1H NMR(400MHz,DMSO-d6):δ=11.45(br s,1H),11.02(br s,1H),7.93-7.86(m,1H),7.85-7.76(m,2H),4.96(J=4.4Hz,2H),2.02(br s,1H),0.94-0.81(m,4H).
步骤6.5化合物12的制备
将2-(1,1-二氧-1,4-噻嗪-4-)乙酸(SM10)(1.63g,8.45mmol)溶于二甲基甲酰胺(20mL)中,依次加入O-(7-氮杂苯并三氮唑-1-)-N,N,N,N-四甲基脲六氟膦盐(3.51g,9.22mmol),N-[5-(肼基酰基)-[1,2,4]***[1,5-a]吡啶-2-]环丙甲酰胺(11)(2g,7.68mmol),最后加入二异丙基乙胺(1.99g,15.37mmol)。20度下搅拌3.5小时。反应液加入水(100mL)中,过滤,固体水洗(20mL),乙醇(40mL)洗,干燥得到N-[5-[[[2-(1,1-二氧-1,4-噻嗪-4-)乙酰基]胺基]氨甲酰基]-[1,2,4]***[1,5-a]吡啶-2-]环丙基甲酰胺(12)(3.26g,89%收率,91%纯度,白色固体)。
LCMS:tR=0.546min in 5-95AB_1.5min_220&254_Shimadzu.lcm,chromatography(Merck RP-18e 25-3mm),MS(ESI)m/z=436.1[M+H]+.
步骤6.6化合物EXP-14的制备
将N-[5-[[[2-(1,1-二氧-1,4-噻嗪-4-)乙酰基]胺基]氨甲酰基]-[1,2,4]***[1,5-a]吡啶-2-]环丙基甲酰胺(12)(300mg,0.689mmol)悬浮溶于吡啶(12mL)加入五硫化二磷二吡啶盐(524mg,1.38mmol)。反应液100度搅拌16小时。反应液过滤,滤液浓缩,制备HPLC分离纯化(basic condition:column:YMC-Triart Prep C18 250*50mm*10um;mobilephase:[water(0.04%NH3H2O+10mM NH4HCO3)-ACN];B%:15%-45%,8min),得到N-[5-[5-[(1,1-二氧-1,4-噻嗪-4-)甲基]-1,3,4-噻二唑-2-]-[1,2,4]***[1,5-a]吡啶-2-]环丙基甲酰胺(EXP-14)(30.4mg,10%收率,97.03%纯度,白色固体)。
LCMS:tR=1.598min in 10-80AB_7min_220&254_Shimadzu.lcm,chromatography(Xtimate C18 2.1*30mm,3um),MS(ESI)m/z=434.1[M+H]+.
HPLC:tR=2.55min in 10-80AB_8min.met,chromatography(Ultimate C18 3um,3.0*50mm).
1H NMR(400MHz,DMSO-d6):δ=11.35(br s,1H),8.22(dd,J=7.2,0.8Hz,1H),7.96-7.91(m,1H),7.89-7.83(m,1H),4.35(s,2H),3.21-3.13(m,4H),3.13-3.05(m,4H),2.08(br s,1H),0.95-0.84(m,4H).
实施例7:化合物EXP-15的制备
合成路线如下:
步骤7.1化合物EXP-15的制备
将N-[5-[5-[(1,1-二氧-1,4-噻嗪-4-)甲基]-1,3,4-噻二唑-2-]-[1,2,4]***[1,5-a]吡啶-2-]环丙基甲酰胺(12)(180mg,0.413mmol)溶于二氯亚砜(3mL)和二甲基甲酰胺(0.3mL)于20度搅拌4小时。反应液浓缩,然后加入饱和碳酸氢钠调节pH=8,再用二氯甲烷(40mL×3)。有机相合并,食盐水(10mL),硫酸钠干燥,过滤,浓缩,制备HPLC分离纯化(HClcondition:column:ACE 5C18-AR 150*30mm*5μm;mobile phase:[water(0.05%HCl)-ACN];B%:10%-40%,8min),得到N-[5-[5-[(1,1-二氧代-1,4-噻嗪-4-)甲基]-1,3,4-恶二唑-2-]-[1,2,4]***[1,5-a]吡啶-2-]环丙基甲酰胺(EXP-15)(27.1mg,14.40%收率,99.73%纯度,盐酸盐,黄色固体)。
LCMS:tR=2.341min in 0-60AB_7min_220&254_Shimadzu.lcm,chromatography(Xtimate C18 2.1*30mm,3um),MS(ESI)m/z=418.2[M+H]+.
HPLC:tR=3.12min in 0-60AB_8min.met,chromatography(Ultimate C18 3um,3.0*50mm).
1H NMR(400MHz,DMSO-d6):δ=11.28(br s,1H),8.00-7.99(m,1H),7.87-7.82(m,2H),4.31(s,2H),3.22(s,8H),2.07(br s,1H),0.93-0.77(m,4H).
实施例8:化合物EXP-16的制备
合成路线如下:
步骤8.1化合物13的制备
将2-(1H-吡唑-4-基)乙醇(SM12)(200mg,1.78mmol),三乙胺(361mg,3.57mmol),二甲氨基吡啶(44mg,0.36mmol)和Boc酸酐(467mg,2.14mmol)溶于二氯甲烷(3mL)中,0-20℃氮气保护下搅拌12小时。将反应液浓缩,得到4-(2-羟乙基)吡唑-1-羧酸叔丁酯(13)(110mg,粗品)黄色油状物直接用于下一步。
步骤8.2化合物14的制备
4-(2-羟乙基)吡唑-1-甲酸叔丁基酯(13)(100mg,0.47mmol),对甲苯磺酰氯(99mg,0.52mmol)和三乙胺(95mg,0.94mmol)溶于二氯甲烷(3mL)中,在0-20℃氮气保护下搅拌2小时,反应液浓缩,得到黄色油状物4-[2-(对甲苯磺酰氧基)乙基]吡唑(14)(120mg,粗品),直接用于下一步。
LCMS:tR=2.850min in 10-80AB_4min_220&254_Shimadzu,chromatography(Xtimate C18,3um,2.1*30mm),MS(ESI)m/z=367.2[M+H]+.
1H NMR(400MHz,DMSO-d6):δ=8.05-7.98(m,1H),7.74(d,J=8.0Hz,2H),7.62(s,1H),7.45(d,J=8.0Hz,2H),4.20(t,J=6.4Hz,2H),2.77(t,J=6.4Hz,2H),2.42(s,3H),1.57(s,9H).
步骤8.3化合物15的制备
将N-[5-(5-甲酰-2-噻吩基)-[1,2,4]***[1,5-a]吡啶-2-基]环丙烷甲酰胺(2)(30mg,0.1mmol)于甲醇(2ml)中,然后加入氰基硼氢化钠(12mg,0.19mmol)。氮气保护下50℃搅拌0.2小时。然后加入碳酸氢钠(1mL),乙酸乙酯(10mL×3)萃取。有机相合并,饱和食盐水(5ml)洗涤,无水硫酸钠干燥,过滤,浓缩,得到N-[5-[5-(羟甲基)-2-噻吩基]-[1,2,4]***[1,5-a]吡啶-2-基]环丙烷甲酰胺(15)(30mg,粗)黄色固体。
LCMS:tR=2.099min in 10-80AB_4.0min_220&254_Shimadzu.lcm,chromatography(Xtimate C18,3um,2.1*30mm),MS(ESI)m/z=315.1[M+H]+.
1H NMR(400MHz,DMSO-d6):δ=11.14(s,1H),8.15(d,J=3.6Hz,1H),7.60-7.52(m,3H),7.03(d,J=3.6Hz,1H),5.58(t,J=5.6Hz,1H),4.64(d,J=5.6Hz,2H),2.01-1.98(m,1H),0.81-0.76(m,4H).
步骤8.4化合物16的制备
将4-[2-(对甲苯磺酰氧基)乙基]吡唑-1-甲酸叔丁酯(14)(23mg,0.06mmol),N-[5-[5-(羟甲基)-2-噻吩基]-[1,2,4]***[1,5-a]吡啶-2-基]环丙烷甲酰胺(15)(20mg,0.06mmol),碳酸铯(21mg,0.06mmol)溶于二甲亚砜(2mL)中的,氮气置换3次,60℃下搅拌0.5小时。加水(6mL),乙酸乙酯(10mL×3)萃取,有机相合并,饱和食盐水(5mL)洗涤,无水硫酸钠干燥,过滤,浓缩,得到N-[5-[5-(4-(2-羟乙基)吡唑-1-羧酸叔丁酯-羟甲基)-2-噻吩基]-[1,2,4]***[1,5-a]吡啶-2-基]环丙烷甲酰胺(16)(27mg,粗)作为黄色固体。
LCMS:tR=1.156min in 5-95AB_1.5min_220&254_Shimadzu.lcm,chromatography(Xtimate C18,3um,2.1*30mm),MS(ESI)m/z=509.2[M+H]+.
步骤8.5化合物EXP-16的制备
N-[5-[5-(4-(2-羟乙基)吡唑-1-羧酸叔丁酯-羟甲基)-2-噻吩基]-[1,2,4]***[1,5-a]吡啶-2-基]环丙烷甲酰胺(16)(27mg,0.05mmol)溶于二氯甲烷(2mL),室温加入三氟乙酸(29mg,0.256mmol),室温氮气保护下搅拌0.5小时,反应液浓缩的粗产品,制备薄层色谱(二氯甲烷:甲醇=10:1)纯化得到标题产品N-[5-[5-[2-(1H-吡唑-4-基)-乙氧基甲基]-2-噻吩基]-[1,2,4]***[1,5-a]吡啶-2-基]环丙烷甲酰胺(EXP-16)(3.0mg,14%收率,白色固体)。
LCMS:tR=1.872min in 10-80AB_4min_220&254_Shimadzu.lcm,chromatography(Xtimate C18 2.1*30mm),MS(ESI)m/z=409.3[M+H]+.
HPLC:tR=2.39min in 10-80CD_8min_met,chromatography(XBridge ShieldRP18 5um).
1H NMR(400MHz,CD3OD):δ=8.13(d,J=4.0Hz,1H),7.80-7.70(m,2H),7.63(dd,J=8.4and 1.2Hz,1H),7.49(s,2H),7.16(d,J=3.6Hz,1H),4.86-4.84(m,2H),4.24-4.20(m,2H),2.93-2.89(m,2H),2.53-2.47(m,1H),1.06-1.03(m,2H),0.90-0.89(m,2H).
实施例9:化合物EXP-17的制备
合成路线如下:
步骤9.1化合物17的制备
N-(5-溴-[1,2,4]***并[1,5-a]吡啶-2-基)-环丙甲酰胺(Int-1)(100mg,0.36mmol),5-羧基-2-噻吩硼酸(SM13)(122mg,0.71mmol)和碳酸钠(113mg,1.07mmol)溶于四氢呋喃(10mL)和水(5mL)中,氮气置换三次后加入1,1-双(二苯基磷)二茂铁氯化钯(50mg,0.07mmol),氮气置换三次后升到100℃搅拌2小时。反应液加水(10mL)用乙酸乙酯(20mL)萃取,有机相用饱和食盐水(10mL)洗涤,无水硫酸钠干燥后过滤,滤液真空浓缩得到5-(2-甲酰基)-噻吩-[1,2,4]***[1,5-a]吡啶-2-环丙烷甲酰胺(17)(50mg,粗品)黄色固体,直接用于下一步。
LCMS:tR=0.783min in 5-95AB_1.5min_220&254_Shimadzu.lcm,chromatography(Xtimate C18,3um,2.1*30mm),MS(ESI)m/z=329.0[M+H]+.
步骤9.2化合物EXP-17的制备
将5-(2-羧基)-噻吩-[1,2,4]***[1,5-a]吡啶-2-环丙烷甲酰胺(17)(50mg,0.15mmol)和2-噻唑-2-基乙胺盐酸盐(SM14)(46mg,0.23mmol)溶于二甲基甲酰胺(2mL)中加入O-(7-氮杂苯并三氮唑-1-基)-N,N,N,N-四甲基脲六氟膦盐(75mg,0.20mmol)和三乙胺(46mg,0.46mol)。反应液于25度下搅拌0.2小时。
反应液浓缩然后制备HPLC[Column:Phenomenex Gemini-NX 150*30mm*5um;Condition:25-55%B(A:water(0.04%NH3.H2O+10mM NH4HCO3);B:CH3CN);Flow rate:25mL/min]纯化得到5-[2-[2-噻唑-2-乙基]甲酰胺基]-噻吩-[1,2,4]***[1,5-a]吡啶-2-环丙甲酰胺(EXP-17)(6.3mg,8%收率,白色固体)。
LCMS:tR=2.468min in 10-80AB_4min_220&254_Shimadzu.lcm,chromatography(Xtimate C18 2.1*30mm),MS(ESI)m/z=439.2[M+H]+.
HPLC:tR=3.51min in 50-100AB_8min_met,chromatography(XBridge ShieldRP18 5um).
1H NMR(400MHz,DMSO-d6):δ=11.21(brs,1H),8.90(t,J=4.8Hz,1H),8.32(d,J=4.0Hz,1H),7.87-7.81(m,2H),7.78-7.68(m,3H),7.61(d,J=3.2Hz,1H),3.65(dd,J=12.8and 7.2Hz,2H),2.58-2.54(m,2H),2.14-2.12(m,1H),0.92-0.86(m,4H).
依据与上述实施例相同的方法,使用市售化合物或参考所示的中间化合物的制备方法而制备以下表4的实施例化合物。
【表4】
实施例10:化合物EXP-19的制备
合成路线如下:
步骤10.1化合物18的制备
4-羟基-N-Boc-哌啶(SM15)(2g,9.94mmol)溶解在四氢呋喃(20mL)中,0℃下分批加入钠氢(1.19g,29.81mmol,60%purity)。搅拌30分钟后,加入二硫化碳(3.03g,39.75mmol,2.40mL)继续搅拌30分钟。碘甲烷(2.82g,19.87mmol)加入后室温反应1小时。反应液倒入水里(20mL),水相用乙酸乙酯(20mL×3)萃取,有机相用无水硫酸钠干燥后过滤浓缩旋干后用硅胶柱层析(洗脱剂:0%~10%乙酸乙酯/石油醚)得到淡黄色目标产物N-叔丁氧羰基哌啶-4-甲基黄原酸酯(18)(1.6g,收率55%)。
1H NMR(400MHz,DMSO-d6):δ=5.74-5.60(m,1H),3.62-3.48(m,2H),3.32-3.23(m,2H),2.55(s,3H),2.02-1.86(m,2H),1.71-1.63(m,2H),1.40(s,9H).
步骤10.2化合物19的制备
1,3-二溴-5,5-二甲基海因(2.21g,7.72mmol)溶解在二氯甲烷(20mL)中,在-75℃下氮气氛围中分批加入氟化氢吡啶溶液(7.14g,72.06mmol)和N-叔丁氧羰基哌啶-4甲基黄原酸酯(18)(500mg,1.72mmol)的二氯甲烷(2mL)溶液。反应液在15-20℃下反应16小时后用饱和碳酸氢钠溶液(20mL)淬灭,水相用乙酸乙酯萃取(20mL×3)。有机相用无水硫酸钠干燥后过滤浓缩旋干后得到黄色目标产物4-(三氟甲氧基)哌啶(19)(400mg,粗品)。
1H NMR(400MHz,DMSO-d6):δ=8.79(s,1H),4.81-4.52(m,1H),3.30-3.17(m,2H),3.16-3.03(m,2H),2.16-1.99(m,2H),1.94-1.72(m,2H).
步骤10.3化合物20的制备
反式-2-氟-N-[5-(5-醛基-2-噻吩)-[1,2,4]***[1,5-a]吡啶-2-基]环丙甲酰胺(7)(180mg,0.54mmol)溶解在四氢呋喃(3mL)中,0℃下加入四氢铝锂(41mg,1.09mmol)。混合反应液在15-20℃下反应2小时后用1M HCl溶液(20mL)淬灭,水相用二氯甲烷萃取(20mL×3)。有机相用无水硫酸钠干燥后过滤浓缩旋干后得到深黄色目标产物反式-2-氟-N-[5-(5-羟甲基-2-噻吩)-[1,2,4]***[1,5-a]吡啶-2-基]环丙甲酰胺(20)(80mg,收率44%)。
1H NMR(400MHz,DMSO-d6):δ=11.33(s,1H),8.26(d,J=4.0Hz,1H),7.74-7.60(m,3H),7.13(d,J=4.0Hz,1H),5.10-4.83(m,1H),4.74(s,2H),2.42-2.36(m,1H),1.65-1.50(m,1H),1.37-1.27(m,1H).
步骤10.4化合物21的制备
反式-2-氟-N-[5-(5-羟甲基-2-噻吩)-[1,2,4]***[1,5-a]吡啶-2-基]环丙甲酰胺(20)(80mg,0.24mmol)溶解在二氯甲烷(2mL)中,0℃下向其中加入二氯亚砜(286mg,2.41mmol)。混合反应液在15-20℃下反应16小时后浓缩旋干得到棕色目标产物反式-2-氟-N-[5-(5-氯甲基-2-噻吩)-[1,2,4]***[1,5-a]吡啶-2-基]环丙甲酰胺(21)(60mg,收率71%)。
步骤10.5化合物EXP-19的制备
反式-2-氟-N-[5-(5-氯甲基-2-噻吩)-[1,2,4]***[1,5-a]吡啶-2-基]环丙甲酰胺(21)(60mg,0.17mmol)溶解在N,N-二甲基甲酰胺(2mL)中,向其中加入碳酸钾(70mg,0.51mmol)和4-(三氟甲氧基)哌啶(19)(58mg,0.34mmol),反应液在15-25℃下反应2小时。反应混合物用二氯甲烷(20mL)和水(20mL)稀释,水相用二氯甲烷(20mL×3)萃取,有机相用饱和食盐水(20mL×3)洗涤,无水硫酸钠干燥后过滤浓缩旋干后采用HPLC纯化(分离柱:Waters Xbridge 150*25mm*5um;流动相:A:水(0.04%NH3.H2O+10mM NH4HCO3)和B:乙腈;梯度:B 50-80%)纯化得到白色固体反式2-氟-N-[5-[5-[5-[[4-(三氟甲基)-1-哌啶]甲氧基]-2-噻吩]-[1,2,4]***[1,5-a]吡啶-2-基]环丙甲酰胺(EXP-19)(1.8mg,收率2%,纯度98.56%)。
LCMS:tR=1.773min in 10-80AB_4min_220&254_Shimadzu.lcm(Xtimate C18,3um,2.1*3mm),MS(ESI)m/z=484.30[M+H]+.
HPLC:tR=2.58min in 10-80AB_8min.met,chromatography.
1H NMR(400MHz,DMSO-d6):δ=11.31(s,1H),8.25(d,J=4.0Hz,1H),7.80-7.55(m,3H),7.15(d,J=4.0Hz,1H),5.06-4.83(m,1H),4.53-4.41(m,1H),3.79(s,2H),2.79-2.71(m,2H),2.43-2.41(m,1H),2.39-2.33(m,2H),1.97-1.87(m,2H),1.80-1.67(m,2H),1.65-1.51(m,1H),1.40-1.27(m,1H).
实施例11:JAK激酶抑制活性检测
将上述实施例的化合物应用于对JAK激酶抑制活性的检测和筛选。
1.方法
在第一块96孔板上每孔加入相应体积DMSO。每孔分别加入20~30μL的100~200μM不同供试化合物储存液。震荡混合3min。对所有化合物进行3X系列稀释。在第二块96孔板上每孔加入60~80μL Kinase buffer,从第一块96孔板每孔取1~2μL溶液加入在第二块96孔板相应孔中。震荡混合3min。从第二块化合物稀释板每孔取5μL化合物稀释液转移到384孔测试板相应孔。在测试板每孔加1~2μL TK Substrate–biotin。每孔加1~2μL酶混合液。同时设置不加酶的blank孔。每孔加1~2μL ATP溶液,封好板子后室温进行反应。反应时间分别为:JAK1:2小时,JAK2:30min,JAK3:30min,TYK2:50min。每孔加3~5μL ofStreptavidin-XL665,3~5μL of TK Antibody-cryptate,封好板子后室温放置30分钟以结束反应。PerkinElmer EnVision机器上读取665nm和620nm的fluorescence。
IC50计算
计算每个孔的HTRF ratio:(665signal/620signal)x 10^4.
抑制百分率基于以下公式计算:
抑制%=(Ratiomax-Ratio化合物)/(Ratiomax-Ratiomin)]×100%
其中Ratio化合物为给定化合物浓度下的HTRF ratio,Ratiomin为加入blank孔的HTRFratio,Ratiomax为不加入化合物的情况下的HTRF ratio。通过使用GraphPad Prism 5.0软件,使用非线性回归模型绘制S型剂量-抑制率曲线并计算IC50值。
Filgotinib表示具有如下结构的化合物:
2.实验结果
各送检化合物测得的IC50(nM)检测值如下表5所示。
【表5】化合物对JAK的抑制活性
备注:IC50值在0-10nM标记为A;10-30nM标记为B;30-50nM标记为C;50-500nM标记为D;大于500nM标记为E;NT代表为未测试。
实施例12:细胞增殖抑制检测
实施例12-1:基于Hela细胞上的增殖抑制检测
方法:
1、细胞铺板:收集培养的细胞并用Vi-Cell XR细胞计数仪进行活细胞计数。用培养基将细胞悬液调整到适当的浓度后加入96-孔细胞培养板中,每孔加50μL-100μL细胞悬液于96-孔细胞培养板,细胞铺板密度取决于细胞的生长速度,细胞置于相应的培养箱中培养。
2、药物处理与OSM刺激
首先用DMSO配制3X倍梯度稀释的系列测试化合物浓度(work solution-1),再用RPMI1640+10%FBS对其进行倍数稀释得到work solution-2;用RPMI1640+10%FBS配制Cisplatin的work solution-2,然后从work solution-2中各取1-10μL加入到已准备好的含培养基的细胞孔中。孵育后,每孔加入1-10μL的OSM的培养基,继续培养。每孔加入适当CTG溶液,震荡混匀1-5分钟后用Envision2104读板仪测定luminescence信号
细胞存活率计算
公式:T/C×100%
其中T为药物处理组的luminescence读数,C为溶剂对照组的luminescence读数平均值。应用GraphPad Prism 5.0软件,使用非线性回归模型绘制S型剂量-抑制率曲线并计算IC50(T/C×100%=50%)值。
实验结果
各送检化合物测得的IC50(nM)检测值如下表6所示。
【表6】化合物对Hela细胞的增殖抑制活性检测
备注:IC50值在0-5uM标记为A;5-30uM标记为B;未检测标记为NT.
实施例12-2:基于BaF3细胞上的增殖抑制检测
方法:
1、细胞铺板:用RPMI1640+10%FBS(含有IL-3)培养基收集培养的细胞并用Vi-Cell XR细胞计数仪进行活细胞计数。用RPMI1640+10%FBS(含有IL-3)培养基将细胞悬液调整到适当的浓度后加入96-孔细胞培养板中,每孔加一定细胞悬液于96-孔细胞培养板,细胞置于相应的培养箱中培养。
2、药物处理:首先用DMSO配制3X倍梯度稀释的系列测试化合物浓度(worksolution-1),再用RPMI1640+10%FBS(含有IL-3)对其进行倍数稀释得到work solution-2;用RPMI1640+10%FBS(含有IL-3)配制Cisplatin的work solution-2,然后从worksolution-2中各取1-10μL加入到已准备好的含培养基的细胞孔中。细胞置相应的培养箱中培养。每孔加入适当CTG溶液,震荡混匀5-15分钟后用Envision2104读板仪测定luminescence信号。
细胞存活率计算
公式:T/C×100%
其中T为药物处理组的luminescence读数,C为溶剂对照组的luminescence读数平均值。应用GraphPad Prism 5.0软件,使用非线性回归模型绘制S型剂量-抑制率曲线并计算IC50(T/C×100%=50%)值。
【表7】化合物对BaF3细胞的增殖抑制活性检测
Code ID | IC<sub>50</sub>(uM) |
EXP-1 | A |
EXP-2 | A |
EXP-3 | A |
EXP-4 | B |
EXP-5 | A |
EXP-6 | NT |
EXP-7 | NT |
EXP-8 | NT |
EXP-9 | NT |
EXP-10 | NT |
EXP-11 | NT |
EXP-12 | NT |
EXP-18 | NT |
EXP-19 | NT |
Filgotinib | B |
备注:IC50值在0-5uM标记为A;5-30uM标记为B;未检测标记为NT.
实施例12-3:基于THP1细胞上的增殖抑制检测
方法:
1、细胞铺板:收集培养的细胞并用Vi-Cell XR细胞计数仪进行活细胞计数。用培养基将细胞悬液调整到适当的浓度后加入96-孔细胞培养板中,每孔加80μL细胞悬液于96-孔细胞培养板,细胞铺板密度取决于细胞的生长速度,细胞置于相应的培养箱中培养。
2、药物处理与IL-4刺激:首先用DMSO配制3X倍梯度稀释的系列测试化合物浓度(work solution-1),再用RPMI1640+10%FBS对其进行倍数稀释得到work solution-2;用RPMI1640+10%FBS配制Cisplatin的work solution-2,然后从work solution-2中各取1-10μL加入到已准备好的含培养基的细胞孔中。细胞置相应的培养箱中培养。孵育后,每孔加入1-10μL的IL-4的培养基,继续培养。每孔加入适当CTG溶液,震荡混匀5-15分钟后用Envision2104读板仪测定luminescence信号。
细胞存活率计算
公式:T/C×100%
其中T为药物处理组的luminescence读数,C为溶剂对照组的luminescence读数平均值。应用GraphPad Prism 5.0软件,使用非线性回归模型绘制S型剂量-抑制率曲线并计算IC50(T/C×100%=50%)值。
【表8】化合物对THP1细胞的增殖抑制活性检测
备注:IC50值在0-5uM标记为A;5-30uM标记为B;未检测标记为NT.
实施例13:肝微粒体的稳定性
使用不同种属(人、大鼠)肝微粒体分别与本发明化合物反应一定时间,通过反应样品与未反应样品的比较而算出残存率,对本发明化合物被肝代谢的程度进行评价。
(结果)表示化合物在10umol/L下的氧化代谢中的残存率。
化合物EXP-3:人的肝微粒体:59.32%;大鼠肝微粒:55.3%。
实施例14:CYP抑制试验
使用市售的混合人肝微粒体,以作为人类主要CYP分子种类(CYP1A2、2B6、2C8、2C9、2C19、2D6和3A4)的典型底物代谢反应的,反应条件如下所述:底物,CYP1A2:30μM的非那西丁;CYP2C9:双氯芬酸10μM;CYP2C19:35μM的S-甲吩妥英;CYP3A4:咪达***为5μM,***为80μM;CYP2D6:丁呋洛尔,10μM;CYP2C8:10μM紫杉醇;CYP2B6:安非他酮70μM;反应时间,CYP1A2、2C9、2D6、2C8、2B6:10分钟;CYP2C19:45分钟;CYP3A4:5分钟。反应温度,37℃。抑制剂(阳性对照),CYP1A2:α-萘黄酮;CYP2C9:磺胺苯唑;CYP2C19:奥美拉唑;CYP3A4:酮康唑;CYP2D6:奎尼丁;CYP2C8:尼卡地平;CYP2B6:氯吡格雷。
在96孔板中准备用于测试化合物和阳性对照的一系列稀释液,将8μL的10mM测试化合物转移到12μL的ACN中。在DMSO:ACN混合物(v/v:40:60)中进行1:3系列稀释。在测定孔中加入HLM,然后在冰上向指定的孔中加入测试化合物或血清稀释的参比抑制剂溶液。在37℃下预孵育96孔板和NADPH溶液5分钟后,将15μL预热的8mM NADPH溶液添加到测定板中以启动反应。孵育时间:3A4 5分钟,1A2、2B6、2C8、2C9和2D6 10分钟,2C19 45分钟。加入含IS的ACN终止反应。
采用s型(非线性)剂量-响应模型(GraphPad Prism 5.0或Xlfit模型205)进行曲线拟合计算IC50,数据计算公式如下:
Y=Bottom+(Top-Bottom)/(1+10^((LogEC50-X)*HillSlope))
X是浓度的对数。Y为浓度由高到低时从下到上呈s形的响应。
结果:化合物EXP-3没有抑制作用。
实施例15:药代动力学研究
对于静脉内途径和口服途径,将化合物配制在5%DMSO+95%羟丙基-β-环糊***溶液中。将试验动物以1-10mg/kg口服给药和以1-5mg/kg静脉内给药。每组包括3只大鼠,经颈静脉穿刺采血约0.2mL,肝素钠抗凝剂,在下面范围内的时间点下采集:0.083h、0.25h、0.5h、1h、2h、4h、6h、8h、10h和24h。将血样采集后于1小时之内以5000-13000rpm离心10min分离血浆,并将血浆样品在LC-MS/MS上分析。
药代动力学参数
通过不同时间点的血药浓度数据,运用Phoenix WinNonlin 7.0计算药代动力学参数,提供AUC0-t、AUC0-∞、MRT0-∞、Cmax、Tmax、和T1/2等参数。通过不同时间点的血药浓度数据,运用Phoenix WinNonlin 7.0计算药代动力学参数,提供AUC0-t、AUC0-∞、MRT0-∞、Cmax、Tmax、和T1/2等参数。
化合物EXP-1药代动力学参数:
口服:AUC是12043h*ng/mL,Cmax是2626ng/mL,T1/2是2.68h.
filgotinib药代动力学参数:
口服:AUC是2849h*ng/mL,Cmax是426ng/mL,T1/2是3.9h.
实施例16:hERG试验
以本发明化合物的心电图QT间隔延长危险性评价为目的,使用表达出humanether-a-go-go related gene(hERG)通道的HEK293细胞,而研究本发明化合物对于心室再极化过程中发挥重要作用的延迟整流K+电流(Ikr)的作用。
使用全自动膜片钳***(patch clamp PC-505B(WARNER instruments)),并通过全自动膜片钳法,将细胞保持在–80mV,然后用持续4秒方波去极化到40mV,再用持续2秒方波超极化到-40mV,以得到hERG尾电流。检测第二个方波引发的最大电流,待其稳定后,灌流测试化合物,当反应稳定后,计算阻断的强度。
细胞外液(mM)为:NaCl,137;KCl,4;CaCl2,1.8;MgCl2,1;HEPES,10;glucose 10;pH7.4(NaOH滴定)。细胞内液(mM)为:K Aspartate,130;MgCl2,5;EGTA 5;HEPES,10;Tris-ATP4;pH 7.2(KOH滴定)。
试验结果:EXP-3:IC50大于10μM。
实施例17:鼠伤寒沙门氏菌回复突变试验
使用沙氏杆菌TA98、TA100、TA1535、TA1537及大肠杆菌作为试验菌株(菌株来源Molecular Toxicology,Inc.),于非代谢活化条件下和活化条件下实施Ames试验,调查本发明的化合物有无基因突变诱发性。
将冷冻保存的菌株进行复苏,接种于营养肉汤培养基中,100~120转/分,37℃恒温振荡器培养11小时。将底层琼脂培养基(含适量琼脂、V-B缓冲液、20%葡萄糖溶液、20%硫酸镁溶液)倒入皿中冷却备用。每个试管中,分别加入0.1mL供试品/阴性对照品(DMSO)/阳性对照品溶液、0.1mL菌液、0.5mL 0.2mol/L磷酸盐缓冲液(PBS)(-S9)/0.5mL S9混合液(+S9)及2.5mL顶层培养基,涡旋混匀后迅速均匀平铺在已铺好的底层琼脂培养基平皿上。自然冷却凝固后,将平皿倒置放入37℃霉菌培养箱内培养48小时。取出培养后的平皿计数,并与DMSO组进行比较而评价,平均回变菌落数为阴性对照组回变菌落数(可视为自发回变数)的2倍或2倍以上(TA1535:3倍或以上),呈剂量-效应关系,则结果为阳性,可判定供试品为致突变剂。反之为阴性。
试验结果:化合物EXP-3为阴性。
实施例18:体内药效模型
18.1CIA模型
18.1.1材料
完全Freund佐剂(CFA)和II型牛胶原购自Chondrex。
18.1.2动物
Lewis大鼠(雌性,10-12周龄)从北京维通利华实验动物技术有限公司获得。将大鼠进行12小时的明暗交替,环境保持温度23±2℃,湿度40~70%。
18.1.3胶原诱导的关节炎(CIA)
用0.05M醋酸溶液配制Ⅱ型胶原溶液(2mg/mL),使之充分溶解,4℃避光放置过夜。试验时在冰浴条件下将2mg/mL的Ⅱ型胶原(CⅡ)溶液与4mg/mL的完全弗氏佐剂(CFA)溶液等体积混合充分乳化。第0天在实验大鼠尾根部皮内注射等体积混合CⅡ(2mg/mL)和CFA(4mg/mL)制备的乳剂进行第一次免疫,在第7天进行第二次增强免疫。
18.1.4研究设计
试验化合物的治疗效果是在大鼠CIA模型中试验的。将大鼠随机分组,每组8只动物。将所有动物在第0天免疫,第7天加强免疫。空白对照(组),溶媒对照组(Vehicle组)是含DMSO的20%HP-β-CD溶液,并且阳性对照组分别用Filgotinib(10mg/kg,给药2周)、枸橼酸托法替布(Tofacitinib组,2mg/kg,给药2周)和乌帕替尼(Upadacitinib组,2mg/kg,给药2周),实验组为分别用2mg/kg、3mg/kg、5mg/kg、10mg/kg的EXP-3给药两周。
18.1.5关节炎的临床评价
足容积同时对四个足趾肿胀进行评分,每只足0~4分,每只大鼠最高评分为16分。0-无肿胀,外观正常;1-踝关节、腕关节或指关节的轻度肿胀或红肿;2-踝关节、腕关节或指关节的中度肿胀或红肿;3-踝关节、腕关节或指关节的重度肿胀或红肿;4-踝关节、腕关节或指关节非常严重的肿胀或红肿。病理评分数据使用SPSS非参数检验Mann-Whitney Utest分析,p<0.05认为是有显著性差异。
18.1.6关节炎发作后的体重、足体积
在临床上,体重减轻和足体积减轻与关节炎相关。因此,关节炎发作后体重和足体积分别与阴性组的差异可以用于评价大鼠模型中的治疗效果。实验数据以Mean±SEM表示;两组间数据采用非配对t检验,p<0.05认为是有显著性差异。
18.1.7试验结果
18.1.7.1受试物对实验大鼠临床观察和体重的影响
所有动物实验期间无肉眼可见明显异常。组动物体重在实验期间稳定增长。Vehicle组动物体重在第1次免疫后8~28天均显著低于组(p<0.01~0.001)。枸橼酸托法替布(Tofacitinib)2mg/kg和EXP-3 10mg/kg组动物体重在第11~17天略有增长,但后续体重又出现回落,其余各给药组动物体重与Vehicle组相近,除了组,其余组均无统计学的显著性差异,说明受试物各组对大鼠体重影响不大。
18.1.7.2受试物对实验大鼠后足足容积的影响
Vehicle组动物在一免后第14~28天足容积显著升高,第24天足容积开始降低。Upadacitinib 2mg/kg组与Vehicle相比在第17~28天足容积显著降低(p<0.05~0.001)。其余各给药组与Vehicle组相比在第21~28天动物足容积均显著降低(p<0.05~0.001)。其中EXP-3 10mg/kg作用最强,且明显强于filgotinib 10mg/kg,其次是Upadacitinib 2mg/kg。EXP-3 5mg/kg~2mg/kg与枸橼酸托法替布(Tofacitinib)2mg/kg作用相近,略弱于乌西替尼(Upadacitinib)2mg/kg。(表10)。表明受试物对CIA模型的大鼠足容积具有一定改善效果。
*p<0.05,**p<0.01,***p<0.001vs.Vehicle
18.1.7.3受试物对实验大鼠四肢关节炎指数(AI)的影响
实验动物在一免后第9~10天开始出现四肢肿胀,在第14天大部分发病足达到2~3分,开始分组给予药物治疗。结果显示,Vehicle组动物AI评分在第11~24天持续升高,第28天略有下降。EXP-3 10mg/kg对降低四肢肿胀的作用最强,其次是tofacitinib 2mg/kg。EXP-3 5mg/kg、EXP-3 2mg/kg与Upadacitinib 2mg/kg作用相近,略弱于tofacitinib 2mg/kg。filgotinib药效最弱。(表11)。表明受试物对CIA模型的大鼠四肢关节炎病情具有一定改善效果。
*p<0.05,**p<0.01,***p<0.001vs.Vehicle。
Claims (10)
1.式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药:
其中:
B独立选自取代或未取代的C3-C6环烷基、芳基、具有1至2个独立选自N、O和S的环杂原子的5至6元杂芳基环,其中所述的C3-C6环烷基或5至6元杂芳环任选地被独立选自卤素、氟代或未氟代的C1-C6烷基、氟代或未氟代的C1-C6烷氧基、氟代或未氟代的C1-C6烷基胺基的一个或多个取代基取代;
D独立选自C,N;
F、G、H、K独立选自C、N、S、O;
L1不存在或独立选自单键,-CH2-,-(CH2)xO(CH2)y-,-(CH2)xNH(CH2)y-,-CH2O-,-C(O)-,-CON(R4)-,-CH2N(R4)-,-CONH(CH2)y-,-N(R4)-,-SO2N(R4)-,-S(O)2-,-N(Me)-;
R4独立选自H、C1-C6烷基、取代的C1-C6烷基、C1-C3醚C1-C3烷基、甲磺酰基;
R1独立选自H、-NH2、-COOH、取代或未取代的C1-C6烷基、酰基、取代的或未取代的酰基胺基、取代的或未取代的C1-C6烷氧基、卤素、羟基、取代的或未取代的C1-C3酯基、取代或未取代的杂芳基;
R2不存在或独立选自H、F、Cl、Me;
R3独立地选自H、取代或未取代的以下基团:磺酰基、磺酰胺基、5至6元杂环,其具有至少一个杂原子且任选地具有独立选自N和S的第二环杂原子、取代的或未取代的C1-C6烷烃,取代基独立选自5至6元杂芳基和甲氧基取代、取代的或未取代的C3-C7环烷基、取代的或未取代的4-7元杂环烷基、取代的或未取代的5-7元杂芳基;
m是0、1、2、3;n是0,1、2、3;p是0、1、2;t是0、1、2、3。
2.权利要求1所述的式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药,其特征在于,B选自取代或未取代的以下基团:环丙烷、环丁烷、吡唑基、吡啶基、咪唑基;取代基选自F、Cl、Br、甲基、乙基、丙基、异丙基、三氟甲基。
3.权利要求1所述的式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药,其特征在于,F、G、H、K不同时为C;优选的,K为S,F、G、H为C。
4.权利要求1所述的式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药,其特征在于,D为C或N;n为1;m为0或者1,优选的,m为0;R2不存在或为H;p为0;t为1。
5.权利要求1所述的式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药,其特征在于,R1独立选自H、-NH2、-COOH、羟基、卤素、取代或未取代的C1-C3烷基、取代或未取代的C1-C3酰基、取代的或未取代的C1-C3酰基胺基、取代的或未取代的C1-C3烷氧基、取代的或未取代的C1-C3酯基;优选的,R1独立选自H、-NH2、-COOH、羟基、卤素、甲基、乙基、丙基、异丙基、甲酰基胺基、甲酯基;L1不存在或独立选自单键,-CH2-,-(CH2)xO(CH2)y-,-(CH2)xNH(CH2)y-,-CONH(CH2)y-,-N(R4)-;R4独立选自H、甲基、乙基、丙基、乙基甲醚、甲基甲醚、乙基***;x或y独立的选自0、1或2;优选的,L1不存在或独立选自单键,-CH2-,-(CH2)xO(CH2)y-,-(CH2)xNH(CH2)y-,-CONH(CH2)y-,-N(R4)-;R4独立选自H、甲基、乙基甲醚;x或y独立的选自0、1或2。
6.权利要求1所述的式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药,其特征在于,R3独立地选自H、取代或未取代的以下基团:磺酰基、磺酰胺基、硫代吗啉1,1-二氧化物、哌啶、吡唑、噻唑、咪唑、1,3,4-噻二唑、哌嗪、吗啉、噻吩、噁唑、1,3,4-噁二唑、呋喃、吡咯、3-吡咯啉、2-吡唑啉、1,2,3-唑、1,2,3-***、1,2,4-***、吡喃;取代基选自H、卤素、C1-C3烷基、C1-C3卤代烷基、羟基C1-C3烷基、C3-C6环烷基、乙基甲醚、甲基甲醚、乙基***;优选的,R3独立地选自H、取代或未取代的以下基团:磺酰基、磺酰胺基、硫代吗啉1,1-二氧化物、哌啶、吡唑、噻唑、咪唑、1,3,4-噻二唑、哌嗪、吗啉、吡嗪、噻吩、噁唑、1,3,4-噁二唑、呋喃、吡咯、3-吡咯啉、2-吡唑啉、1,2,3-唑、1,2,3-***、1,2,4-***、吡喃;取代基选自H、卤素、甲基、乙基、丙基、异丙基、三氟甲基、羟乙基、羟甲基、环丙烷、环丁烷、乙基甲醚、甲基甲醚、乙基***。
7.权利要求1所述的式(I)所示的化合物或其立体异构体、互变异构体或其药学上可接受的盐或其溶剂合物或者前药,其特征在于,R3独立地选自H、取代或未取代的以下基团:磺酰基、磺酰胺基、硫代吗啉1,1-二氧化物、哌啶、吡唑、噻唑、咪唑、1,3,4-噻二唑、哌嗪、吗啉、噻吩、噁唑、1,3,4-噁二唑、呋喃、吡咯、3-吡咯啉、2-吡唑啉、1,2,3-唑、1,2,3-***、1,2,4-***、吡喃;取代基选自C1-C3卤代烷氧基;优选的,R3独立地选自H、取代或未取代的以下基团:磺酰基、磺酰胺基、硫代吗啉1,1-二氧化物、哌啶、吡唑、噻唑、咪唑、1,3,4-噻二唑、哌嗪、吗啉、吡嗪、噻吩、噁唑、1,3,4-噁二唑、呋喃、吡咯、3-吡咯啉、2-吡唑啉、1,2,3-唑、1,2,3-***、1,2,4-***、吡喃;取代基选自三氟甲氧基。
9.一种药物组合物,其包含权利要求1~7任一项所述的化合物或其立体异构体、互变异构体或其药学上可接受的盐,和药学上可接受的载体。
10.权利要求1~6任一项所述的化合物在用于制备预防或治疗JAK激酶相关疾病药物中的用途,优选是在制备用于预防和/或治疗涉及软骨退化、骨和/或关节退化的疾病、涉及炎症或免疫响应的病症、内毒素驱动的疾病状态、癌症和器官移植排斥的药物中的应用;更优选的,是在制备用于预防和/或治疗骨关节炎、克隆病、类风湿性关节炎、银屑病、过敏性气道疾病、幼年特发性关节炎、结肠炎、炎性肠病、内霉素驱动的疾病状态、软骨更新损伤的疾病、先天软骨畸形、器官移植排斥、涉及软骨退化、关节退化、骨髓增殖性障碍、白血病、实体瘤的药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910721525 | 2019-08-06 | ||
CN2019107215257 | 2019-08-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111892592A true CN111892592A (zh) | 2020-11-06 |
CN111892592B CN111892592B (zh) | 2023-09-19 |
Family
ID=73245765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010776163.4A Active CN111892592B (zh) | 2019-08-06 | 2020-08-05 | Jak激酶抑制剂及其用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220274983A1 (zh) |
EP (1) | EP4011880A4 (zh) |
CN (1) | CN111892592B (zh) |
WO (1) | WO2021023207A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022161205A1 (zh) * | 2021-01-29 | 2022-08-04 | 珠海联邦制药股份有限公司 | 一种含有jak抑制剂或其盐或其晶型的口服制剂及其制备方法和应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1541216A (zh) * | 2001-07-20 | 2004-10-27 | - | 8-甲氧基-(1,2,4)***并(1,5-a)吡啶衍生物及其作为腺苷受体配体的应用 |
WO2009047514A1 (en) * | 2007-10-10 | 2009-04-16 | Cancer Research Technology Limited | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use |
CN101878212A (zh) * | 2007-08-31 | 2010-11-03 | 默克雪兰诺有限公司 | ***并吡啶化合物及其作为ask抑制剂的用途 |
CN102105471A (zh) * | 2008-07-25 | 2011-06-22 | 加拉帕戈斯股份有限公司 | 用于治疗变性和炎性疾病的新化合物 |
CN102131390A (zh) * | 2008-06-20 | 2011-07-20 | 健泰科生物技术公司 | ***并吡啶jak抑制剂化合物和方法 |
CN102203093A (zh) * | 2008-09-08 | 2011-09-28 | 西格诺药品有限公司 | 氨基***并吡啶和其作为激酶抑制剂的用途 |
CN105061420A (zh) * | 2015-06-04 | 2015-11-18 | 南京旗昌医药科技有限公司 | 一种jak抑制剂的晶型及其制备方法和应用 |
CN107759587A (zh) * | 2016-08-19 | 2018-03-06 | 中国医药研究开发中心有限公司 | [1,2,4]***并[1,5‑a]吡啶类化合物及其制备方法和医药用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1894931A1 (en) * | 2006-08-30 | 2008-03-05 | Cellzome Ag | Triazole derivatives as kinase inhibitors |
WO2010010188A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
ES2734048T3 (es) * | 2015-04-29 | 2019-12-04 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibidores de Janus cinasas (JAK) |
WO2016179207A1 (en) * | 2015-05-05 | 2016-11-10 | Concert Pharmaceuticals, Inc. | Deuterated filgotinib |
CN108349974B (zh) * | 2016-02-02 | 2021-04-30 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡啶酰胺类化合物及其应用 |
CN108341814B (zh) * | 2017-01-23 | 2021-09-03 | 上海翔锦生物科技有限公司 | Jak激酶抑制剂及其应用 |
CN111320624B (zh) * | 2018-12-14 | 2023-05-12 | 中国医药研究开发中心有限公司 | ***并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途 |
-
2020
- 2020-08-05 US US17/631,596 patent/US20220274983A1/en active Pending
- 2020-08-05 EP EP20849907.9A patent/EP4011880A4/en active Pending
- 2020-08-05 WO PCT/CN2020/107028 patent/WO2021023207A1/zh unknown
- 2020-08-05 CN CN202010776163.4A patent/CN111892592B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1541216A (zh) * | 2001-07-20 | 2004-10-27 | - | 8-甲氧基-(1,2,4)***并(1,5-a)吡啶衍生物及其作为腺苷受体配体的应用 |
CN101878212A (zh) * | 2007-08-31 | 2010-11-03 | 默克雪兰诺有限公司 | ***并吡啶化合物及其作为ask抑制剂的用途 |
WO2009047514A1 (en) * | 2007-10-10 | 2009-04-16 | Cancer Research Technology Limited | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use |
CN102131390A (zh) * | 2008-06-20 | 2011-07-20 | 健泰科生物技术公司 | ***并吡啶jak抑制剂化合物和方法 |
CN102105471A (zh) * | 2008-07-25 | 2011-06-22 | 加拉帕戈斯股份有限公司 | 用于治疗变性和炎性疾病的新化合物 |
CN102203093A (zh) * | 2008-09-08 | 2011-09-28 | 西格诺药品有限公司 | 氨基***并吡啶和其作为激酶抑制剂的用途 |
CN105061420A (zh) * | 2015-06-04 | 2015-11-18 | 南京旗昌医药科技有限公司 | 一种jak抑制剂的晶型及其制备方法和应用 |
CN107759587A (zh) * | 2016-08-19 | 2018-03-06 | 中国医药研究开发中心有限公司 | [1,2,4]***并[1,5‑a]吡啶类化合物及其制备方法和医药用途 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022161205A1 (zh) * | 2021-01-29 | 2022-08-04 | 珠海联邦制药股份有限公司 | 一种含有jak抑制剂或其盐或其晶型的口服制剂及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2021023207A1 (zh) | 2021-02-11 |
CN111892592B (zh) | 2023-09-19 |
EP4011880A4 (en) | 2023-09-13 |
US20220274983A1 (en) | 2022-09-01 |
EP4011880A1 (en) | 2022-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101874030B (zh) | 用作食欲素受体拮抗剂的吡咯烷和哌啶 | |
RU2632870C2 (ru) | Трициклические гетероциклические соединения и ингибиторы jak | |
RU2642777C2 (ru) | Производные 2-аминопиразина в качестве ингибиторов csf-1r киназы | |
US9956220B2 (en) | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors | |
CA2782720A1 (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
JP6895396B2 (ja) | 疾患を処置するためのgls1阻害薬 | |
JP2023027203A (ja) | ピリミジン化合物及びその医薬用途 | |
US20080242677A1 (en) | Imidazolidinone derivatives | |
US9475817B2 (en) | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors | |
AU2018236290A1 (en) | MK2 inhibitors, synthesis thereof, and intermediates thereto | |
KR20170096599A (ko) | 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물 | |
TW201125865A (en) | Oxadiazole derivative having inhibion activity on endothelial lipase | |
CA3120037A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
JP2006522784A (ja) | 炎症疾患の治療でp38MAPキナーゼインヒビターとして使用の5‐アミノ‐2‐カルボニルチオフェン誘導体 | |
US20220185816A1 (en) | Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine | |
CN113072542B (zh) | RORγt抑制剂及其制备方法和用途 | |
CN111892592A (zh) | Jak激酶抑制剂及其用途 | |
JP2004521903A (ja) | TGF−β阻害剤としてのチアゾール化合物 | |
JP2024501281A (ja) | Irak4阻害剤としての2h-インダゾール誘導体及び疾患の治療におけるそれらの使用 | |
JP7235859B2 (ja) | 新規なチアゾール誘導体及びその薬学的に許容される塩 | |
KR102086999B1 (ko) | 피롤로[2,3-d]피리미딘 화합물 또는 그 염 | |
AU2018278284A1 (en) | Carboxylic acid derivatives of pyridoquinazolines useful as protein kinase inhibitors | |
CA3152021A1 (en) | Substituted (7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino compounds useful as jak1 inhibitors | |
CN114075188A (zh) | 芳香杂环酰胺类化合物及其制备方法和医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: JAK kinase inhibitors and their applications Effective date of registration: 20231226 Granted publication date: 20230919 Pledgee: Nanjing Branch of Jiangsu Bank Co.,Ltd. Pledgor: JIANGSU CAREPHAR PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980073240 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |